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The goal of this thesis was to evaluate the use of artificial transposon systems for the 
generation of recombinant cell pools and cell lines with Chinese hamster ovary (CHO) cells 
as the production host. Transposons are naturally occurring genetic elements present in the 
genome of most organisms. Several transposons of metazoan origin have been engineered 
to facilitate the integration of one or more recombinant genes (transgenes) into the genome 
of the host cell. In this thesis, three of the most commonly used transposons, piggyBac 
(PB), Tol2, and Sleeping Beauty (SB), were used for transgene delivery into CHO-DG44 
cells. The transposon systems described here involves co-transfection of the host cells with 
a helper plasmid for the transient expression of the transposase, and a donor plasmid coding 
for the transgene and a gene for the selection, both positioned between two transposon 
repeat sequences that are required for DNA transposition. The tumor necrosis factor 
receptor Fc fusion protein (TNFR:Fc) was used as the model protein for most experiments. 
Through the optimization of various selection parameters we showed that PB-mediated cell 
pools can be generated with selection duration of as little as 5 days in the presence of 
puromycin. All three transposon systems, PB, Tol2, and SB, resulted in cell pools with 
similar volumetric TNFR:Fc productivities that were about 9 times higher than those 
generated by conventional plasmid transfection. Transposon-mediated cell pools had 10 – 
12 transgene integrations per cell. However, we demonstrated that some the integration 
events occurred via DNA recombination rather than transposition. We also isolated clonal 
cell lines from cell pools. As expected, the average volumetric TNFR:Fc productivity of 
transposon-derived cell lines was higher than that of cell lines generated by conventional 
transfection. In 14-day fed-batch cultures, protein levels up to 900 mg/L and 1.5 g/L were 
obtained from transposon-mediated cell pools and cell lines, respectively. The stability over 
time of the volumetric productivity of cell pools was determined by maintaining the cells 
in culture for 3 months in the absence of selection. In general, the productivity decreased 
to 50 % its initial level over the first 7 weeks in culture and then remained constant for the 
following 5 weeks. In contrast, the volumetric protein yield from transposon-mediated cell 
lines remained constant for up to 4 months in the absence of selection. We also showed that 
the three transposon systems could be used for cell pool generation with CHO-K1 and 
CHO-S with similar volumetric productivities as observed with CHO-DG44 cells. Finally, 
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we utilized the PB transposon system for generating cell pools co-expressing up to 4 
different transgenes, enhanced green fluorescent protein (EGFP), secreted alkaline 
phosphatase (SEAP), and the light and heavy chains of an IgG1 monoclonal antibody, by 
simultaneous transfection of all four transgenes. We showed that PB-mediated cell pools 
had increased volumetric productivity of each of the proteins compared to those generated 
by conventional co-transfection. The use of the PB transposon system increased the 
percentage of cells in the pools that were co-expressing all four proteins as compared to the 
results with cell pools generated by conventional transfection. In conclusion, the 
transfection of CHO cells with the PB, Tol2 or SB transposon system is a simple, efficient, 
and reproducible approach to the generation of cell pools and cell lines for the rapid 
production of recombinant proteins.  
Keywords: recombinant protein, CHO cells, piggyBac, Tol2, Sleeping Beauty, transposon, 





L’objectif de cette thèse était d’évaluer l’application de systèmes basés sur les 
"transposons" pour obtenir des lignées et des pools de cellules recombinantes utilisant 
comme hôte de production les cellules CHO (Chinese hamster ovary cells – Cellules 
ovariennes d'hamster chinois).  Les transposons sont des éléments génétiques naturels 
présents dans le génome de la plupart des organismes vivants. Un grand nombre de 
transposons d’origine métazoaire ont été modifié génétiquement afin de faciliter 
l’intégration d’un ou plusieurs gènes recombinants (transgènes) dans le génome de 
différentes cellules hôtes. Dans cette thèse ont été évalués les trois transposons les plus 
fréquemment utilisés, c’est à dire piggyBac  (PB), Tol2 et Sleeping Beauty (SB), pour leur 
capacité à insérer les transgènes dans les cellules de la lignée CHO-DG44. Le système de 
transposons utilisé ici comporte la co-transfection de deux vecteurs plasmidiques,  le 
"helper" pour l’expression transitoire de l’enzyme transposase, et le "donor", codant pour 
le transgène et le gène de la résistance aux antibiotiques utilisé pour la sélection clonale : 
les deux gènes du plasmide "donor" sont chacun entourés des deux séquences répétitives  
nécessaires pour la transposition dans l’ADN. La protéine recombinante utilisée comme 
modèle dans la plupart des expériences était le TNFR :Fc, produit de la fusion du récepteur 
au facteur de nécrose tumorale et de la partie constante d’une immunoglobuline (Fc). Grâce 
à l’optimisation de plusieurs paramètres de sélection nous avons démontré qu’avec PB, il 
est possible de générer des pools après une période de sélection à la puromycin en 
seulement 5 jours. Les trois système de transposons, PB, Tol2 et SB ont donné des pools 
avec des productivités similaires entre eux (TNFR :Fc) et environ 9 fois supérieures aux 
titres obtenus avec la méthode standard de transfection  plasmidique. Les pools générés par 
transposition ont montré 10 – 12 intégrations individuelles par cellule. Nous avons 
démontré qu’une partie de ces intégrations était le résultat de recombinaison et non pas de 
transposition. Nous avons également isolé des lignées cellulaires clonales à partir des pools. 
La moyenne de production volumétrique de TNFR :Fc dans les lignées dérivés par 
transposition était supérieure à celle des lignées générées par transfection conventionnelle. 
Dans des cultures fed batch de 14 jours le niveau de productivité  obtenu étaient de 900 
mg/L et 1.5 g/L, respectivement pour les pools dérivés par transposition et les lignées 
générées par transfection conventionnelle. La stabilité dans le temps de cette production a 
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été testée dans des cultures maintenues durant une période de trois mois en l’absence de 
sélection.  En général, la productivité est descendue à un niveau de 50% par rapport à la 
valeur initiale pendant les 7 premières semaines de culture puis est restée stable pendant 5 
semaines successives. Par contre, la productivité volumétrique des lignées clonales 
générées par transposons est restée constante jusqu’à 4 mois en absence de sélection. Nous 
avons aussi validé l’utilisation des trois systèmes de transposons PB, Tol2 et SB pour la 
production de pools recombinantes avec d’autres lignées cellulaires, CHO-K1 et CHO-S, 
avec productivités volumétriques similaires à celles observées dans les CHO-DG44. Enfin 
nous avons utilisé le système PB transposon pour générer des pools recombinants qui co-
expriment quatre transgènes différents  insérés simultanément  par co-transfection: l’EGFP 
(enhanced green fluorescence protein), la SEAP (secreted alkaline phosphatase), les deux 
chaines légère et lourde d’une immunoglobuline IgG1.  Nous avons pu démontrer que les 
pools générés par transposition avec PB avaient une productivité supérieure pour toutes les 
protéines en comparaison avec les pools générés par transfection conventionnelle. En 
conclusion, la transfection des cellules CHO avec  les systèmes de transposons PB, Tol2 
ou SB représente une approche simple, reproductible et efficace pour la création de lignées 
et pools de cellules transgéniques pour la production rapide de protéines recombinantes. 
Keywords: protéine recombinante, cellules CHO, piggyBac, Tol2, Sleeping Beauty, 
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1.1. Therapeutic Recombinant Proteins 
The biotechnology industry is a $140 billion industry with 246 biopharmaceutical products 
on the market (Walsh 2014). These products are targeted to a wide range of diseases 
including cancers and autoimmune disorders. The therapeutic proteins available can be 
categorized into different molecular types including antibody-based drugs, anticoagulants, 
blood factors, bone morphogenetic proteins, engineered protein scaffolds, enzymes, Fc 
fusion proteins, growth factors, hormones, interferons, interleukins, and thrombolytics 
(Carter 2011). 
Recombinant human insulin (Humulin®) created at Genentech, developed by Eli Lilly, and 
approved by the US Food and Drug Administration (FDA) in 1982 was the first human 
protein therapeutic derived from recombinant DNA technology in E. coli (Walsh 2005). 
Human tissue plasminogen activator (tPA) produced in Chinese hamster ovary (CHO) cells 
in 1986 by Genentech was the first therapeutic protein from recombinant mammalian cells 
(Wurm 2004). Since then, the recombinant therapeutic protein market has been growing at 
a steady rate. The percentage of therapeutic proteins among the new drugs approved by the 
USA Food and Drug Administration (FDA) increased from 17% in 2005 to 32% in 2011 
(Kling 2011). The total sales of biologics in United States in 2012 reached ~$63.6 billion, 
an 18.2% increase over 2011 sales (Aggarwal 2014). In the last 15 years (1999-2013), 113 
first in class drugs were approved by the FDA of which 30% were biologics (Eder et al. 
2014).  
Among the different kinds of therapeutic proteins, monoclonal antibodies (mAb) are the 
highest selling class of biologics with mAb sales reaching $63 billion in 2013 (Walsh 
2014). There are currently 40 US Food and Drug Administration (FDA)-approved mAbs, 
with their sales constituting ~38.5% of the total biologics market (Aggarwal 2014).  
In this thesis, most of the studies were conducted using the tumor necrosis factor receptor-
Fc fusion protein (TNFR:Fc). Fusion proteins are created by joining the genes encoding 2 
or more different proteins. They exhibit properties of their component parts. The fusion of 
the Fc region of immunoglobulins with other proteins has been the most successful among 





recombinant proteins by increasing half-life, facilitating expression and secretion, enabling 
facile purification by protein A affinity chromatography, improving solubility and stability, 
and enhancing potency by increasing valency (Carter 2011; Huang 2009). The sales in US 
of Fc fusion proteins had a growth rate of ~35.3% in 2012, which was the highest among 
biologics (Aggarwal 2014). The most successful drug of this class has been etanercept 
(Enbrel®), a TNFR2:Fc fusion protein produced by Amgen. It was the top-selling protein 
therapeutic in 2013 with $8.8 billion in world-wide sales in rheumatoid arthritis and other 
autoimmune diseases (Walsh 2014).  
1.2. Protein production in CHO cells 
The variety of hosts for protein production extends from microbial to transgenic animals 
and plants. However, cultivated mammalian cells remain the principal hosts for therapeutic 
protein production due to their ability to perform human-like post-translational 
modifications (PTMs) (Wurm 2004; Zhu 2012). About 60% of the biopharmaceuticals 
approved between 2010 and 2014 are produced from mammalian cells (Walsh 2014). Some 
of the cell lines commonly used for mammalian cells include CHO, human embryonic 
kidney (HEK-293), human retina-derived PerC6, baby hamster kidney (BHK), and mouse 
myeloma-derived NS0 (Jayapal et al. 2007; Li et al. 2010; Wurm 2004). Among these, 
CHO cells are most commonly used for therapeutic protein production (Walsh 2014).  
CHO cells have been grown in culture for more than 50 years since their discovery in 1957 
by Theodore Puck (Puck 1957). CHO cells are well-characterized and have been 
demonstrated to be a safe host as they are not receptive to human viruses (Kim et al. 2012; 
Lai et al. 2013). They can also be easily adapted to chemically defined media (Butler and 
Spearman 2014). The ability of CHO cells to grow to high cell densities in single-cell 
suspension culture contributed to their attractiveness as a production host (Hacker et al. 
2010). Also, CHO cells have the capacity for efficient post-translational modification, and 
they produce recombinant proteins with glycoforms that are both compatible with and 
bioactive in humans (Kim et al. 2012). The product yield from recombinant CHO cells has 
improved more than 20-fold over the past two decades, and this improved product yield 






There are a number of CHO strains that exhibit different phenotypes in cell culture (Wurm 
2013). In this thesis, I have worked with three of these: CHO-DG44, CHO-K1, and CHO-
S. 
1.2.1. CHO-K1 
The proline-dependent CHO-K1 cell strain was generated from the original CHO cell line 
by single-cell cloning in late 1960s (Wurm 2013). The first published CHO genome was 
that of CHO-K1 (Xu et al. 2011). CHO-K1 cells have been commonly used with the 
glutamine synthase (GS) selection system (Bebbington et al. 1992; Daramola et al. 2014; 
Fan et al. 2013; Knox et al. 2013). The GS gene is co-transfected along with the GOI and 
the GS inhibitor methionine sulphoximine (MSX) is used to inhibit endogenous GS activity 
such that only transfectants with additional GS activity to overcome this selection can 
survive. This system based on CHO-K1 is one of the most popular methods for selection 
of recombinant CHO cell lines. There are several licensed pharmaceutical products that 
were made with the help of the GS system in combination with CHO-K1 cells (Wurm 
2013). 
1.2.2. CHO-DG44 
The popularity of CHO cells for recombinant protein production increased after the 
isolation of cell lines harboring mutations in the dihydrofolate reductase (DHFR) gene 
(Kaufman et al. 1985; McCormick et al. 1984; Scahill et al. 1983). The cell line DXB11 
(or DUKX) was generated in 1980 by deletion of one DHFR allele and an inactivating 
mutation in the second allele from CHO-K1 through chemical mutagenesis (Urlaub and 
Chasin 1980). The cell line CHO-DG44 was generated by deleting both DHFR alleles from 
CHO-pro3-strain, another derivative of the original CHO cell line, by two rounds of gamma 
irradiation and then screening for the absence of DHFR activity. These two DHFR-minus 
strains require glycine, hypoxanthine, and thymidine (GHT) for growth (Urlaub et al. 
1983). They are used as hosts for recombinant protein production since the absence of 
DHFR activity serves as a method for selection following transfection of the cells with the 
gene of interest (GOI) and the DHFR gene. Recombinant cells are then selected by growth 





productivity by surviving cells, selection for the DHFR gene often involves exposure of the 
cells to methotrexate (MTX), a chemical inhibitor of DHFR (Wurm 2004). Selection in the 
presence of MTX usually results in amplification of the exogenous DHFR gene and the 
GOI. These advantages of selection and amplification made CHO-DG44 cells one of the 
most widely used host systems for protein production. 
1.2.3. CHO-S 
The CHO cells were first adapted to grow in suspension cultures in 1960s. Unfortunately, 
there is lack of clarity and scientific credit for the origin of CHO-S cells (Wurm 2013). 
CHO-S cells were first mentioned in 1973 (Thompson and Baker 1973). There is now a 
commercially available cell line adapted for growth in suspension culture using 
FreeStyle™ CHO medium (Life Technologies), also designated as CHO-S. Even though 
the commercially available CHO-S could have been derived from the original CHO-S, 
these two cell lines are expected to differ phenotypic and genetically (Wurm 2013). 
1.3. Protein production strategies using mammalian cells 
1.3.1. Stable cell line generation  
Recombinant protein production from stable CHO cell lines is the most widely used 
manufacturing approach in the biopharmaceutical industry (Wurm 2004). Stable gene 
expression involves the expression of the recombinant protein from cell lines in which the 
transgene(s) has been stably integrated into the genome of the host cell. The process of 
generation of a recombinant cell line involves several steps. The first step in cell line 
generation is the delivery of the GOI to the target cells, followed by a genetic selection step 
to eliminate the non-recombinant cells. Then, by single-cell cloning, cell lines with the 
phenotypes such as robust cell growth and high protein expression and protein quality are 
recovered.  
To create stably transfected mammalian cell lines an efficient selection system is required 
to eliminate non-recombinant cells and achieve high protein expression levels (Van 
Blokland et al. 2011). Raising the stringency of selection often helps to reduce the number 





cell line (Wurm 2004). This can be achieved by increasing the concentration of the selection 
agent in the culture medium, but this approach has its limits due to the toxicity of the agent 
(Van Blokland et al. 2007). Well-established selection strategies rely upon 
complementation of a host auxotrophy, as described above. In CHO cells, the two most 
commonly used selection systems are based on the DHFR and GS systems as described in 
Section 1.2. However, use of MTX and MSX in high concentrations promotes amplification 
of the integrated recombinant genes, which is known to cause chromosomal 
rearrangements, leading to clonal variability in regards to growth, productivity, and 
stability (Chusainow et al. 2009). 
A common alternative to the auxotrophic selection method is the use of genes conferring 
resistance to antibiotics such as geneticin (G418), hygromycin B, zeocin, blasticidin or 
puromycin. With this strategy, transfected cells are selected in medium containing the 
appropriate antibiotic. The antibiotics target different cellular pathways from protein 
synthesis to transcription (Darken 1964; Drocourt et al. 1990; Gonzalez et al. 1978). The 
pool of cells recovered after selection is highly heterogeneous in terms of specific protein 
productivity and cell growth. This necessitates the isolation and evaluation of several 
hundred individual cells to recover a few candidate production cell lines that possess the 
desired characteristics. 
There are several methods for generating single-cell clones. The conventional method, 
limiting dilution, is time-consuming and low-throughput (Browne and Al-Rubeai 2007). 
Recently, several automated methods have been developed to select for high-producing cell 
lines including methods using flow cytometry and cell sorting and methods based on 
individual protein secretion amounts (e.g. Matrix – based secretion assays) (Akselband et 
al. 2003; DeMaria et al. 2007; Holmes and Al-Rubeai 1999; Kacmar and Srienc 2005). 
They have significantly reduced the time frame required to screen large number of clones. 
However, in some cases these methods are expensive and can be limited by the need for 
specific antibodies to the therapeutic proteins generated or by the need to optimize the 
experimental conditions to a specific cell line (Browne and Al-Rubeai 2007). A better 





influence the integration of the GOI, which will be described in detail in the following 
sections. 
Protein production from cell lines is a well-established technology with FDA-approved 
guidelines. It is the preferred method for the production of marketed recombinant proteins 
as each cell line is derived from a single cell and is expected to be a homologous cell 
population with little to no variability, a very valuable attribute in terms of product quality. 
Cell lines are high-yielding with volumetric productivities up to 10 g/L, and they can stably 
express the protein of interest for extended periods of time. This stability allows them to be 
scalable up to 20,000 L without any loss in productivity. However, stable cell line 
development is still a time-consuming process taking several months to complete (Browne 
and Al-Rubeai 2007; Matasci et al. 2008; Wurm 2004).  
1.3.2. Transient gene expression  
During preclinical stages of drug development, only milligram to gram quantities of 
recombinant proteins are required. Due to the long time-frame for the generation of stable 
cell lines, transient gene expression (TGE) in suspension-adapted mammalian cells, is often 
employed as a rapid method for the production of moderate quantities of proteins to meet 
these needs (Geisse and Voedisch 2012; Hacker et al. 2013; Pham et al. 2006). TGE 
involves expression of transgenes from episomal plasmid DNA in a heterogeneous cell 
population. The entire process from DNA delivery to protein recovery takes about 1 – 3 
weeks (Daramola et al. 2014; Rajendra et al. 2011). Also, TGE can be used for producing 
proteins that are cytotoxic to cells. Recent improvements in TGE with CHO cells, by 
employing cell line engineering and process optimization strategies, have resulted in 
protein yields of 1 – 2 g/L (Cain et al. 2013; Daramola et al. 2014; Rajendra et al. 2011). 
However, the relatively large amounts of plasmid DNA required for transfection and the 
difficulty in working at large volumetric scales limit the usefulness of TGE. 
1.3.3. Stable cell pools 
An alternative approach for the rapid production of a moderate amount of protein is through 





recombinant cells obtained by transgene delivery and genetic selection but without the 
subsequent single cell cloning steps. This methodology is commonly used for the 
evaluation of expression vectors and cell line engineering (Majors et al. 2008). For cell line 
development in industry, cell pools are usually generated for the recovery of clonal 
production cell lines.  
Use of cell pools for therapeutic protein production is not traditionally preferred due to the 
heterogeneity of the cell population and the transgene expression instability. Accordingly, 
production cell lines are derived from a single cell, in order to minimize heterogeneity. 
However, we are now aware of the possibility of occurrence of intraclonal variation in the 
genotype of cells (Pilbrough et al. 2009; Wurm 2013). This contributes to the instability of 
clones, resulting in a heterogeneous population not unlike a cell pool. Hence, cell pool 
generation has recently gained interest for rapid production of protein. Even though stably 
transfected cell lines will continue to be the method of choice for protein manufacturing, 
cell pools can be used as an alternative to TGE for rapid production of proteins for use 
during the early phases of drug discovery. The main advantages of cell pools over TGE are 
the low DNA requirement, the ease of scalability, and the potential for high volumetric 
yields (Fan et al. 2013; Li et al. 2013; Ye et al. 2010). There is also the possibility of 
maintaining a frozen cell pool bank to allow multiple consecutive production runs. Cell 
pools are advantageous to clonal cell lines because of shorter and less costly development 
times (Ye et al. 2010). 
There are few publications on the development of cell pools as a method for recombinant 
protein production (Fan et al. 2012; Li et al. 2013; Ye et al. 2010). Volumetric 
productivities of up to 600 mg/L, using fluorescence-activated cell sorting (FACS) to enrich 
the cell pool in recombinant cells, have been achieved (Ye et al 2010). With the use of 
specific DNA elements appended to the transgene expression cassette, productivities of up 
to 1 g/L have also been achieved (Ye et al. 2010). However, the volumetric productivity of 
these cell pools was reduced by 40 % per week in culture. Cell pools with volumetric 
productivities up to 900 mg/L were obtained from an optimized fed-batch process by using 
GS-knockout cells coupled with a weakened promoter for selection of the exogenous GS 





pools as a method for generating material for preclinical stages of therapeutic protein 
development such as toxicology tests and first human dose (FHD) analysis They have 
successfully generated cell pools with high productivities using technologies to express the 
antibody and selection marker as a single mRNA (personal communication, Dr. Chetan 
Goudar). 
1.4. DNA integration methods for cell line generation 
1.4.1. DNA recombination 
The majority of the available methods for cell line generation rely on integration through 
DNA recombination of the exogenous DNA with the cellular genome. The resulting 
recombinant cells differ in protein expression due to lack of control over gene copy number 
and the chromosomal context of the integrated genes. This leads to differences in the 
productivity and stability of transgene expression among the cells. Consequently, a large 
number of candidate recombinant cell lines (routinely 500-1000) must be screened to find 
a few which express the protein of interest stably at the desired level (Table 1.1) (Matasci 
et al. 2008). 
For recombinant cell lines, the stability of protein expression over time strongly depends 
on the integration site of the heterologous DNA in the host cell genome, known as position 
effect variegation (PEV) (Eissenberg et al. 1992; Wilson et al. 1990). Integration near or 
within transcriptionally-inactive heterochromatin leads to little or no transgene expression 
and may result in unstable protein production (Kouzarides 2007; Whitelaw et al. 2001). 
Even if the gene integrates into transcriptionally-active euchromatin, production instability 
may occur due to gene loss or transcriptional silencing (Chusainow et al. 2009; Kim et al. 
2011; Osterlehner et al. 2011). When the transgene is integrated into the cellular 
chromosomes, the gene expression levels are affected by the chromatin structures around 
the integrated genes. Hence several strategies are being employed to improve the efficiency 





1.4.2. DNA regulating elements 
Many strategies to obtain position-independent transgene expression rely on the use of 
DNA regulating elements (Barnes and Dickson 2006; Kwaks and Otte 2006). They are 
specific DNA sequences appended to the transgene expression cassette within the plasmid. 
These DNA boundary sequences are able to block the formation of condensed chromatin 
(heterochromatin), and thus may help to obtain stable transgene expression irrespective of 
the chromosomal integration site (Matasci et al. 2008). Until now, a number of cis-acting 
elements have been applied to enhance the expression and stability of protein production 
in CHO cells. These DNA elements include insulators, locus control regions (LCRs), 
scaffold or matrix attachment regions (S/MARs), antirepressor elements, and ubiquitous 
chromatin opening elements (UCOEs). LCRs are complex transcriptional enhancers that 
impart an integration-position-independent and copy-number-dependent expression pattern 
to linked transgenes (Dean 2006). Insulators are DNA sequence elements that help protect 
transgenes against chromatin-mediated silencing by increasing the local concentration of 
factors that promote formation of unfolded structure of chromatin i.e. euchromatin 
(Gaszner and Felsenfeld 2006). Another class of cis-acting elements is the S/MAR, which 
maintains the chromatin structure in an “active” configuration through the creation of 
chromatin loops that curb the silencing of the transgene (Galbete et al. 2009; Gorman et al. 
2009). Although this element can increase the protein productivity, the exact mechanism 
of its action is currently unknown (Kim et al. 2012). Antirepressor or STAR (stabilizing 
and antirepressor) elements function by affecting the spread of DNA methylation and 
histone deacetylation patterns from the surrounding genome into the recombinant DNA 
(Kwaks et al. 2003). Another commonly used element is the UCOE, derived from the 
promoters of housekeeping genes, which allows position-independent, long-term transgene 
expression (Antoniou et al. 2003; Williams et al. 2005). 
It has been demonstrated that the inclusion of S/MARs or UCOEs in expression vectors 
increases protein production and the stability of transgene expression in mammalian cells 
(Benton et al. 2002; Dharshanan et al. 2014; Grandjean et al. 2011). Additionally, the vector 
engineering required for using DNA regulating elements is simple which makes it easily 





and the plasmid integration efficiency is only slightly improved by the AT richness of these 
DNA elements (Allen et al. 2000).  
1.4.3. Targeted DNA integration 
Alternative approaches to improving volumetric protein production and stable transgene 
expression rely on targeted integration of a single copy of the gene into highly transcribed 
sites within the host cell genome. This can be accomplished by means of heterologous site-
specific recombination or targeted integration. This allows a stable level of transgene 
expression over an extended period of time (Barron et al. 2007; Sorrell and Kolb 2005). 
Cre/loxP (cyclization recombinase/ loxP) and FLP/FRT (flipase/ FLP recombinase target) 
are the most commonly used site-specific recombination methods for cell line generation 
(Crawford et al. 2013; Zhou et al. 2010). Both allow the location and timing of gene 
expression to be closely regulated. It is based on the ability of recombinase genes (cre or 
FLP) to effect recombination between pairs of DNA sequences (loxP or FRT) that flank a 
genomic region of interest (Sadowski 1995; Sauer and Henderson 1988; Sternberg 1981). 
However, they require the flanking recognition sites at the target genomic locus which 
would enable the homologous recombination. Thus, it requires the construction of a host 
cell line with these specific recognition sites, which is laborious and time-consuming. Also, 
these DNA recombinases are known to have low recombination efficiencies (Table 1.1) 
(Cheng and Alper 2014).  
Another strategy for targeted DNA integration is the use of directed DNA nucleases. These 
are engineered nucleases composed of sequence-specific DNA-binding domains fused to a 
nonspecific DNA cleavage module. These chimeric nucleases enable efficient and precise 
genetic modifications by inducing targeted DNA double-strand breaks (DSBs) that 
stimulate the cellular DNA repair mechanisms, including error-prone non-homologous end 
joining (NHEJ) and homology-directed repair (HDR) (Gaj et al. 2013). The commonly used 
nucleases are zinc finger nucleases (ZFNs), transcription activator-like effector nucleases 
(TALENs), and the recently discovered clustered regularly interspaced short palindromic 
repeats (CRISPR) and CRISPR-associated Cas9 nuclease system (Cheng and Alper 2014). 





more commonly used as a genome editing tool for generating engineered cell lines for 
protein production (Fan et al. 2012).  
The challenge for these methodologies, however, is to identify a “hotspot” in the genome 
that supports sufficiently stable and high production of biologic products with a low 
transgene copy number, which makes it a difficult technique to adopt for recombinant 
protein production (Table 1.1) (Crawford et al. 2013). 
Table 1.1. Summary of advantages and disadvantages of the different gene integration 
methods for cell line generation 




Advantages Simple to use 
Disadvantages 
Low integration efficiency/random integration 
Large screen size required to identify suitable clone 
Labor intensive and time consuming 
Site directed method 
(e.g. Cre/loxP, Flp/FRT) 
Advantages 
Site directed integration 
Low integrated copy number/improved stability 
Potential reduction in screen size to identify suitable 
clone 
Disadvantages 
Complex & requires specific host cell line 
generation 
Low integration efficiency 
Cis-regulating elements 
method 
(e.g. UCOE, MAR, STAR) 
Advantages 
Simple to use 




Multiple options/requires optimization 
Transposon based 
method 
EVALUATED DURING THE COURSE OF THIS THESIS 
 
1.4.4. Transposon systems 
DNA transposon elements have recently been used to catalyze the integration of 
recombinant genes into mammalian cells for recombinant protein production (Alattia et al. 
2013; Li et al. 2013; Matasci et al. 2011). DNA transposons are naturally occurring genetic 
elements with the ability to move and replicate within the host. They have been used as 
tools for non-viral gene delivery by insertional mutagenesis and transgenesis with 
applications in gene therapy (Izsvak and Ivics 2004; Meir et al. 2013). Transposon systems 





single DNA copies with high frequency at multiple loci (Ivics et al. 2009). The class II 
transposons are most commonly used for research and gene therapy. They function by the 
means of a “cut-and-paste” mechanism. The system consists of two components; a 
transposase and a pair of inverted terminal repeats (ITR) that carry the transposase binding 
sites necessary for transposition. The dual vector systems that are typically used consist of 
a donor vector, carrying an artificial transposon with a mammalian expression cassette for 
the recombinant transgene and selection marker flanked by the ITRs, and a helper vector 
for transient expression of the transposase (Ding et al. 2005). Co-transfection of the two 
vectors permits an efficient “cut and paste” transfer of the transposon from the donor 
plasmid into the genome (Fig. 1.1) (Wilson et al. 2007). Such transposon systems can be 
effectively used for the generation of recombinant cell lines for protein production; 
however, only limited progress has been made in this field (Alattia et al. 2013; Kahlig et 
al. 2009; Li et al. 2013; Matasci et al. 2011).  
 
Figure 1.1. Schematic representation of the transposition of an artificial transposon by transiently 
produced transposase for the generation of stable cell pools. 
The most widely used transposon systems for gene transfer in mammalian cells are 
piggyBac (PB), Tol2, and Sleeping Beauty (SB) (Mates et al. 2007). The PB transposon is 
derived from the cabbage looper moth Trichoplusia ni, and has been shown to transpose 
efficiently in mice and human cells (Wilson et al. 2007; Wu et al. 2006). The hAT-like 
(hobo, Activator, Tam3) Tol2 transposon, isolated from the Japanese medaka fish (Orizyas 
latipes), is the only known naturally active vertebrate transposon (Koga et al. 1996). It is a 





effectively in frog, chicken, mouse, and human cells (Kawakami 2007). The SB transposon 
was reconstructed from inactive copies of Tc1/mariner like elements found in a fish genome 
(Ivics et al. 1997). The SB system has been extensively used as a tool for genetic 
modifications in somatic tissues of a wide range of vertebrate species including humans 
and the germline of fish, frogs, mice, and rats (Hackett et al. 2005; Huang et al. 2010; Mates 
et al. 2007). Significant efforts have been made to enhance the transposition efficiency for 
PB and SB transposases resulting in very effective transposases, namely mPB and SB100X, 
respectively (Cadinanos and Bradley 2007; Mates et al. 2009). 
Apart from having different phylogenetic origins, the three transposon systems also differ 
in their biochemical properties that affect their activities. Different transposon families 
display various DNA insertion sequence preferences (Table 1.2). The Tc1/mariner family 
targets the dinucleotide TA and the piggyBac family targets TTAA tetranucleotides 
whereas the Tol2 system has a heterogenic target sequence site (Grabundzija et al. 2010). 
Another main property is overproduction inhibition (OPI), which limits the transposition 
activity with increasing intracellular transposase concentration. The susceptibility of SB 
system to OPI is better documented as compared to that of PB and Tol2 (Balciunas et al. 
2006; Grabundzija et al. 2010; Lohe and Hartl 1996; Wilson et al. 2007; Wu et al. 2006). 
Another important factor to consider is the cargo size limitation of the transposons (Table 
1.2). Currently, the SB system seems to be the most limited with 50 % reduction in 
transposition efficiency with cargo size of 6 kB compared to 2 kb (Geurts et al. 2003). Tol2 
and PB transposases are known to be able to integrate up to 10 and 14 kb, respectively, 
without a significant reduction in transposition efficiency (Balciunas et al. 2006; Ding et 
al. 2005). Comparisons of integration profiles of the three TP systems in human cells 
showed that PB and Tol2 transposons integrate in intragenic regions and near 
transcriptional start sites whereas SB transposon integration occurred randomly across the 
genome, nevertheless in transcriptionally active regions (Grabundzija et al. 2010; Huang et 
al. 2010; Meir et al. 2011). This reduces the risk of the position effect and transcriptional 






Table 1.2. Differences between three transposon systems 
 PiggyBac Tol2 Sleeping Beauty 
Origin 
Cabbage looper moth 
(Trichoplusia ni) 
hAT superfamily- 
endogenous in medaka 
fish 
Inactive Tc1/mariner-
like elements found in 
fish genome 
Commonly used in Mouse, human cells 
Zebrafish (mainly), 
frog, chicken, mouse 
cells 
Fish, frogs, mice, rats 
Transposase gene size ~1.8 kb ~2 kb ~1 kb 
Maximum transposon 
size 
Up to 14 kb >10 kb ~6 kb 
Target site TTAA - TA 
AT % in ITR 60 – 70% 77% 67% 
 
There have been several studies comparing the activities and integration profiles of PB, 
Tol2, and SB transposon systems in human cells for applications in gene therapy 
(Grabundzija et al. 2010; Huang et al. 2010; Meir et al. 2011; Wu et al. 2006). Recently, 
the PB transposon system has been explored for the generation of stable pools and clonal 
cell lines for recombinant protein production (Alattia et al. 2013; Kahlig et al. 2009; Li et 
al. 2013; Matasci et al. 2011) . It has been shown that recombinant protein production and 
the efficiency of cell pool and cell line generation can be significantly improved using the 
PB transposon system in comparison to cell line generation by plasmid integration by DNA 
recombination (Matasci et al. 2011). 
A summary of the advantages and disadvantages of the various DNA integration methods 







1.5. Thesis Objectives 
The goal of this thesis is to study transposon-mediated recombinant cell pool and cell line 
generation and to determine if this technology results in efficient recombinant protein 
production with CHO cells. The specific aims can be broadly classified as: 
1. Characterization of PB, Tol2, and SB transposon systems for the generation of 
cell pools and cell lines 
2. Generation and characterization of PB-mediated multi-transgene expressing cell 
pools 
The gist of work done in each chapter are as follows: 
1.5.1. Optimization of parameters for efficient transposon mediated cell pool 
 generation and comparison with traditional methods 
PB transposon has been recently shown to improve the efficiency of recombinant CHO cell 
line generation (Matasci et al. 2011). However, use of the PB transposon system for cell 
pool generation was not explored. This chapter focuses on identifying the critical 
parameters influencing the generation of cell pools with CHO-DG44 cells. Both the 
duration of the selection period and the time post-transfection for the initiation of selection 
were investigated. In cell pools generated by conventional transfection methods, the 
selection agent is known to influence the selection stringency, which may affect volumetric 
productivity and the stability of transgene expression (Wurm 2004). Hence, four different 
antibiotics were assessed for the generation of cell pools. After an optimized selection 
procedure, a simple batch process to assess TNFR-Fc productivities was performed. The 
stability of protein production with cell pools is an important factor and hence was studied 
over a period of 90 days in culture. Further experiments were designed and executed to 






1.5.2. Comprehensive study of PB, Tol2 and SB transposon systems for recombinant 
 protein production 
This chapter focuses on the comparison of the PB, Tol2 and SB transposon systems for the 
generation of cell pools and cell lines with CHO-DG44 cells. The overall aim was to study 
the similarities and differences of the three transposon systems for recombinant protein 
production. We used the mouse-codon-optimized PB transposase gene (mPBase), a 
mammalian codon-optimized Tol2 transposase, and the hyperactive SB transposase 
(SB100X) for this study (Cadinanos and Bradley 2007; Mates et al. 2007). The ratio of 
helper and donor plasmid DNA necessary for efficient generation of cell pools was 
evaluated. Real time quantitative PCR (RT-qPCR) was employed for analysis of the 
integrated transgene copy number and the steady state mRNA levels in comparison with 
cell pools derived from conventional plasmid transfection. Cell lines were recovered from 
cell pools generated using all three transposon systems. The stability of transgene 
expression in cell pools and cell lines was also studied for a period of up to 3 months in the 
absence of selection. Finally, cell pools and cell lines were subjected to a simple fed-batch 
production process to assess volumetric productivities.  
1.5.3. Study of the three transposon systems for cell pool generation in different CHO 
 cell strains 
The heterogeneity of cell lines is a recognized problem which makes the standardization of 
protein production strategies difficult. CHO-DG44, CHO-K1 and CHO-S are the most 
commonly used CHO cell strains in the biopharmaceutical industry. Although these cell 
lines share a common lineage, they are known to exhibit different phenotypes in cell 
culture. To improve the applicability of transposon systems for cell pool and cell line 
generation, the PB, Tol2 and SB transposon systems were used to generate cell pools in 
CHO-DG44, CHO-K1 and CHO-S cells. An analysis of the integrated transgene copy 
number was performed to compare the activities of the three transposons in the three 
different CHO strains. The stability of protein production for the cell pools was analyzed 





1.5.4. Cell pools expressing multiple transgenes using the PB transposon for gene 
 delivery 
In biomedical research and drug development there is often a need for multiple genes to be 
co-expressed. Conventional approaches include transfection of host cells with multiple 
expression cassettes either carried in a single plasmid or in multiple plasmids. This often 
results in inefficient integration and expression of transgene due to the low efficiency of 
plasmid integration events. Another method involves sequential transfection followed by 
recombinant cell cloning for each individual transgene (McPhaul and Berg 1986; Paul et 
al. 1985). In this chapter, we studied the use of the PB transposon system for the 
simultaneous delivery of multiple genes into CHO-DG44 cells for obtaining cell pools co-
expressing multiple proteins, with the goal to simplify multi-transgene cell pool and cell 
line generation. Two separate strategies were tested in the presence and absence of the PB 
transposon. First, all the transgenes were selected with a single antibiotic. Then the different 
transgenes were each selected with a different antibiotic. The average integrated copy 
number of each transgene in each cell pool was analyzed. Cell lines were recovered from 
the cell pool expressing 3 proteins. The percentage of cells co-expressing all the transgenes 
transfected in a pool were also evaluated using three different fluorescent proteins, EGFP, 
























2.1. Routine cell culture 
Suspension-adapted CHO-DG44, CHO-K1 or CHO-S cells were grown in serum-free 
ProCHO5 medium (Lonza AG, Verviers, Belgium) supplemented with 13.6 mg/L 
hypoxanthine, 3.84 mg/L thymidine, and 4 mM glutamine (SAFC Biosciences, St. Louis, 
MO). The cells were maintained in 5-10 mL of medium in 50-mL Tubespin bioreactors 
(TS50) (TPP AG, Trasadingen, Switzerland) or in 100 mL of medium in glass bottles 
agitated by orbital shaking as previously described (Muller et al. 2005). The cells were 
passed twice per week at an inoculation density of 3 x 105 cells/mL. The cell number and 
viability were assessed manually by the Trypan Blue exclusion method. 
2.2. Plasmids 
The donor vector pMP-PB (Fig. 2.1A) and the helper vector pmPBase have been described 
previously (Matasci et al. 2011). In pMP-PB the transgene and the puromycin N-acetyl-
transferase (pac) gene were expressed from the mouse cytomegalovirus major immediate 
early promoter (p-mCMV) and the herpes simplex virus thymidine kinase promoter (p-
HSV-tk), respectively. The human elongation factor 1 alpha first intron was present in the 
5’ untranslated region (5’ UTR) of the transgene mRNA. The bovine growth hormone 
polyadenylation element (BGH-pA) was used for termination and 3’ end processing of the 
transgene mRNA. For each PB donor plasmid, the artificial transposon, enclosed between 
the inverted terminal repeats (ITRs) specific for the PB transposon system, consisted of the 
expression cassette of the transgene and that of the selection marker (Fig. 2.1A). The donor 
plasmids expressing different transgenes were constructed by introducing the respective 
transgenes into the multiple cloning site (MCS) of pMP-PB. The light and heavy chains for 
the IgG1 monoclonal antibody were obtained from pMP-PB-LC and pMP-PB-HC, 
respectively (Matasci et al. 2012). The gene for the fluorescent proteins Cerulean and 
mCherry were obtained from Dr. Iacovos Michael (EPFL) in the plasmids, PB-CA-
Cerulean and PB-CA-mCherry, respectively. The gene for secreted alkaline phosphatase 
(SEAP) was obtained from Prof. Fussenneger (ETH, Zurich). Donor plasmids coding for 
resistance against different antibiotics were constructed by replacing the pac gene with the 





The donor plasmids for the Tol2 and SB transposon systems were constructed such that the 
only difference between them was the identity of the ITR sequences. The ITRs for Tol2 
transposon system were cloned from the plasmid pMiniTol2-CMVpA, obtained from the 
University of Wuerzburg (Germany) (Balciunas et al. 2006). The ITRs for the SB 
transposon system were cloned from the vector pT2/HB, purchased from Addgene 
(Middlesex, UK). The name and organization of the resulting plasmids are provided in 
Table 2.1. The schematic representation of the resulting plasmids is shown in Fig 2.1A. 
The helper plasmid pmPBase carries an expression cassette for the transient production in 
mammalian cells of a codon-optimized PBase gene. The gene was transcribed from the 
human cytomegalovirus major immediate early promoter (p-hCMV). The other helper 
plasmids, pmTol2ase and pSBase were constructed by replacing the mPBase gene in 
pmPBase with a mammalian codon-optimized Tol2 transposase gene and the SB100X 
transposase gene to generate pmTol2ase and pSBase, respectively (Fig. 2.1B). The enzyme 
Tol2ase was cloned from the plasmid pKate-N-Tol2 obtained from the University of 
Wuerzburg (Germany) (Balciunas et al. 2006). This sequence was codon-optimized for 
mammalian cells by Life Technologies. The SB100X gene was cloned from the vector 








Figure 2.1. Representation of the maps of donor and helper vectors. (A) Donor pDNAs for different 
transposon systems were generated by substituting the respective 3’ and 5’ ITRs in the same backbone. 
Different genes of interest were cloned into each plasmid to create the donor vector for each transposon 
system expressing the respective protein. (B) All three transposase enzymes were cloned into the same 
expression cassette driven by human CMV promoter. Abbreviations: p-mCMV – mouse cytomegalovirus 
major immediate early promoter; p-HSV-TK – herpes simplex virus thymidine kinase promoter; ITR – 
inverted terminal repeat; BGH-pA – bovine growth hormone polyadenylation element; SV40-pA - simian 






Table 2.1. List of plasmids used 





TNFR:Fc pMP-PB-TNFR:Fc pac/ Puromycin PiggyBac 
EGFP pMP-PB-EGFP pac/ Puromycin PiggyBac 
IRES-EGFP pMPPB-IRES-EGFP pac/ Puromycin PiggyBac 
TNFR:Fc pSB-BPB-TNFR:Fc bsr/ Blasticidin PiggyBac 
TNFR:Fc pSB-HPB-TNFR:Fc hph/ Hygromycin PiggyBac 
TNFR:Fc pSB-ZPB-TNFR:Fc Sh ble/ Zeocin PiggyBac 
TNFR:Fc-IRES-EGFP pMPIG-TNFR:Fc pac/ Puromycin PiggyBac 
IgG - LC pMP-PB-LC pac/ Puromycin PiggyBac 
IgG - HC pMP-PB-HC pac/ Puromycin PiggyBac 
SEAP pSB-PPB-SEAP pac/ Puromycin PiggyBac 
IRES-EGFP pSB-BPB-IRES-EGFP bsr/ Blasticidin PiggyBac 
SEAP pSB-HPB-SEAP hph/ Hygromycin PiggyBac 
IgG - HC pSB-ZPB-HC Sh ble/ Zeocin PiggyBac 
Cerulean pSB-PPB-Cer pac/ Puromycin PiggyBac 
mCherry pSB-PPB-mCh pac/ Puromycin PiggyBac 
EGFP pSB-PTol2-EGFP pac/ Puromycin Tol2 
IRES-EGFP pSB-PTol2-IRES-EGFP pac/ Puromycin Tol2 
TNFR:Fc pSB-PTol2-TNFR:Fc pac/ Puromycin Tol2 
EGFP pSB-PSB-EGFP pac/ Puromycin Sleeping Beauty 
IRES-EGFP pSB-PSB-IRES-EGFP pac/ Puromycin Sleeping Beauty 
TNFR:Fc pSB-PSB-TNFR:Fc pac/ Puromycin Sleeping Beauty 
TNFR:Fc pMP-TNFR:Fc pac/ Puromycin -None- 
aAbbreviations: bsr: blasticidin S-resistance gene; hph: hygromycin B phosphotransferase gene; Sh ble: ble 
gene from Streptoalloteichus hindustanus; bla: beta-lactamase gene; IgG – LC: immunoglobulin G light 
chain; IgG – HC: immunoglobulin G heavy chain; TNFR:Fc: tumor necrosis factor receptor Fc fusion; IRES: 
internal ribosome entry site (from encephalomyocarditis virus (EMCV)); EGFP: enhanced green fluorescent 







2.3. DNA Transfection 
Suspension-adapted CHO-DG44 cells were transfected using linear 25 kDa 
polyethylenimine (PEI) (Polysciences, Eppenheim, Germany) prepared as a solution of 1 
mg/mL in deionized water at pH 7.0. The day before transfection, the cells were seeded in 
ProCHO5 at a density of 2 x 106 cells/mL and grown overnight in an orbitally shaken glass 
bottle as described (Muller et al. 2005). On the day of transfection, cells were centrifuged 
and resuspended in 5 mL of ProCHO5 in TS50s at a density of 3 x 106 cells/mL. To each 
culture, 22.5 µg of plasmid DNA and 45 µg of PEI were separately added (Rajendra et al. 
2011). If necessary, sheared herring sperm DNA (Invitrogen AG, Basel, Switzerland) was 
used as a non-specific (filler) DNA to keep the total amount of transfected DNA constant 
(Rajendra et al. 2012). The tubes were then incubated with agitation at 37°C at 180 rpm.  
2.4. Generation of recombinant cell pools and cell lines 
In the standard protocol for the generation of cell pools, cells were co-transfected with the 
donor and helper plasmid DNA at a ratio of 9:1 (w/w) unless mentioned otherwise. Control 
transfections in the absence of a helper plasmid were performed with filler DNA at the 
same ratio as above. At two days post-transfection, the cells were inoculated at a density of 
5 x 105 cells/mL in 5 mL of ProCHO5 and 10 µg/mL puromycin in TS50s. Cells were 
passed every 3-5 days for 10 days in selective medium by inoculation at 5 x 105 cells/mL 
(Fig. 2.2). After the removal of selection pressure, the cell pools were allowed to recover 
for 2 -3 days. The cells were then either subjected to a 4-day batch process or a 2-week fed-
batch process by seeding at 3x105 cells/mL (Fig. 2.2). For the 2-week fed-batch cultures of 
cell pools and clonal cell lines, cells were seeded at a density of 5 x 105 cells/mL at 37 °C. 
After three days, the cultures were fed with 3 g/L glucose and 1.5 g/L essential and non-
essential amino acids and treated with 0.25 % dimethyl acetamide (DMA).Incubation was 
continued at 31°C. 
To study the stability of transgene expression over time, the cell pools were maintained in 






Figure 2.2. Schematic diagram of the standard protocol for the generation of cell pools.  
Clonal cell lines expressing TNFR:Fc were recovered by limiting dilution from cell pools 
after 10 days of selection in puromycin. Briefly, cells were seeded in 96-well plates with 
100 µl of ProCHO5 medium (10 % conditioned medium) to a cell density to allow the 
plating of 0.5 cells per well. After 15-20 days in culture, individual colonies of cells were 
transferred to a 24-well plate and cultivated in suspension by agitation of the plates on an 
orbital shaker. After one cell passage in 24-well plates, aliquots of cells were seeded in 24-
well plates at a 1:10 dilution in ProCHO5 medium (approximately 0.5 x 106 cells/mL). The 
TNFR:Fc concentration in the medium after 4 days was measured by ELISA as described 
below. 
2.5. ELISA 
TNFR:Fc and IgG concentrations in cell culture medium were directly determined by 
sandwich ELISA using a modified version of a published protocol (Meissner et al. 2001). 
Briefly, a goat anti-human IgG or an Fc-specific goat anti-human IgG F(ab’)2 fragment 





well plates for the analysis of IgG and TNFR:Fc, respectively. For both assays, captured 
protein was detected with alkaline phosphatase-conjugated goat anti-human gamma chain 
IgG (Life Technologies) using p-nitrophenyl phosphate (p-NPP) (AppliChem GmbH, 
Darmstadt, Germany) as a substrate. Absorption was measured at 405 nm using a 
microplate reader (SPECTRAmax TM340; Molecular Devices, Palo Alto, CA, USA). 
Human TNFR:Fc (Enbrel®) (Amgen, Zug, Switzerland) and human IgG (Jackson 
ImmunoResearch Laboratories, Inc.) were used to generate standard curves.  
2.6. Flow Cytometry 
EGFP measurements were performed using a guava easyCyte® microcapillary flow 
cytometer (Merck-Millipore, Schaffhausen, CH) with excitation and emission wavelengths 
of 488 and 532 nm, respectively. Cells were prepared for analysis by dilution in PBS to 
densities of 100 – 400 × 105 cells/mL. Each sample was measured in duplicate with a 
minimum of 5,000 recorded events. 
Fluorescence from cell pools expressing Cerulean, EGFP and mCherry was measured using 
the BD™ LSR-II flow cytometer (BD Biosciences). The excitation and emission 
wavelengths used for Cerulean, EGFP, and mCherry were 405 – 450/50 nm, 488 – 525/50 
nm, and 561 – 610/20 nm, respectively. Cells were prepared for analysis by dilution in PBS 
to densities of 400 – 1000 × 105 cells/mL. Each sample was measured in duplicate with a 
minimum of 50,000 recorded events. 
2.7. Quantification of secreted alkaline phosphatase (SEAP) activity 
The SEAP activity in cell culture medium was determined by colorimetry using a modified 
version of a published protocol (Schlatter et al. 2002). Briefly, an aliquot of cell culture 
was centrifuged, and 50-µL of the supernatant was transferred into a chamber of a 96- well 
plate. The plate was then incubated at 37 °C. The substrate, p-nitrophenyl phosphate 
(AppliChem GmbH, Darmstadt, Germany), was added to 2X SEAP assay buffer (1 mM 
MgCl2, 21% diethanolamine, pH 9.8) to a final concentration of 12 mM. The solution was 
heated to 37°C and added to each well having cell culture supernatant. Absorbance readings 





Devices, Palo Alto, CA, USA) every minute for 15 min, and the maximum linear reaction 
rate was determined in order to calculate the SEAP activity as described (Schlatter et al. 
2002). 
2.8. Quantification of transgene copy number 
For each analysis, 1 x 106 cells were collected by centrifugation, washed twice with cold 
PBS, flash frozen in liquid nitrogen, and stored at -80 °C. Total DNA was extracted from 
cells using the DNeasy Blood & Tissue kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s protocol. Real time quantitative PCR (RT-qPCR) was carried out in a 
LightCycler 480 Real-Time PCR System (Roche Applied Science, Basel, Switzerland) 
with the ABsolute QPCR SYBR Green ROX mix (Axon Lab AG, Baden-Dättwil, 
Switzerland) according to the manufacturer’s instructions. Oligonucleotide primers for 
amplification of each gene are listed in Table 2.2. Standard curves to determine the copy 
number of each gene were created with known amounts of the appropriate plasmid 
following its quantification by UV absorbance. 
Table 2.2. Oligonucleotide primers used in this study for RT-qPCR. 
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) 
TNFR:Fc  GCCAGACCAGGAACTGAAAC GTGGATGAAGTCGTGTTGGA 
bla  ACGATCAAGGCGAGTTACATGA ACACTGCGGCCAACTTACTTCT 
EGFP GTCTATATCATGGCCGACAAGC GGTGTTCTGCTGGTAGTGGTC 
SEAP GTATGTGTGGAACCGCACTG GAGTCTCGGTGGATCTCGTATT 
IgG – LC  CTGGAATTCACCATGAGTGTGC CTACAGATGCAGACAGGGAGGA 
IgG – HC  ACAGGTGAAACTGCTCGAGTCT TGAAGGTGAATCCAGACGCTAC 
CHO β – actin  GCTCTTTTCCAGCCTTCCTT GAGCCAGAGCAGTGATCTCC 
2.9. Quantification of transgene mRNA 
At the time of sampling for ELISA from a 4-day batch culture, 1 x 106 cells were recovered 
and stored frozen at -80 °C. After thawing the cells, total RNA was extracted from cells 
using the GenElute mRNA kit (SAFC Biosciences) according to the manufacturer’s 
protocol. The samples were treated with 1 unit of RNase-free DNase I (Invitrogen) for 15 
min at room temperature. The DNase I was inactivated by incubation at 75 °C for 15 min. 





Biosciences) primed with oligonucleotide dT. RT-qPCR was performed as described in 
section 2.8. The oligonucleotide primers for amplification of the TNFR:Fc and cellular β-
actin cDNAs are listed in Table 2.2. The relative amount of TNFR:Fc mRNA was 















Identifying Parameters for Efficient 













Heterogeneous populations of stably transfected cells (cell pools) can be used for rapid 
production of moderate amounts of recombinant proteins. They have a very low DNA 
requirement for transfection, are easily scalable, and have the potential for higher 
volumetric yields compared to TGE and have considerably shorter developmental time 
frames than SGE. Limited efforts have been made towards the development of efficient 
cell pool generation methods. Published articles on the generation of cell pools describe 
selection schemes of relatively long duration, low volumetric protein productivities, and 
protein production instability as the key issues (Fan et al. 2013; Ye et al. 2010).  
The PB transposon system has been shown to have a high integration efficiency in 
mammalian cells (Ding et al. 2005; Wilson et al. 2007; Wu et al. 2006). This transposon is 
known to integrate into transcriptionally active regions of the cell’s genome, which is 
expected to improve transgene transcription levels and recombinant protein productivities 
(Galvan et al. 2009; Grabundzija et al. 2010; Meir et al. 2011; Wilson et al. 2007). The PB 
transposon system has been recently used for the generation of recombinant CHO and 
HEK293 cell lines and HEK293 cell pools with considerable success (Alattia et al. 2013; 
Kahlig et al. 2009; Li et al. 2013; Matasci et al. 2011). However, the PB system has not 
been used for the generation of CHO cell pools.  
Here, we aim to establish methods for PB-mediated cell pool generation. The PB system 
consists of one plasmid (helper vector) for the transient expression of the PBase gene and 
a second plasmid (donor vector) carrying the 5′ and 3′ inverted repeat elements (5′IR and 
3′IR) delimiting the ends of the artificial transposon carrying the GOI (Kahlig et al. 2009; 
Meir et al. 2011). To begin, several parameters including the duration of selection and the 
ratio of helper:donor plasmid DNA were optimized. The choice of antibiotic and its 
concentration are known to influence the selection stringency, thereby affecting volumetric 
productivity and the stability of transgene expression (Wurm 2004). Here, we chose to 
evaluate 4 different antibiotics for selection, namely puromycin, blasticidin, hygromycin 
B, and zeocin for the optimization of the selection conditions for cell pool generation. Using 





volumetric productivity was determined in a 14-day batch process. Finally, the stability of 







3.2.1. Optimization of selection duration and initiation for PB-mediated cell pools 
Starting with a previously published method for the selection of CHO cells following 
transfection with the PB transposon system, we optimized the duration of selection for the 
generation of CHO cell pools (Matasci et al. 2011). CHO-DG44 cells were co-transfected 
with pMPIG-TNFR:Fc and pmPBase at a ratio of 9:1 (w/w). At 2 days post-transfection, 
the cells were grown in the presence of 10 µg/mL puromycin for up to 10 days. The 
percentage of viable cells in the population was determined daily. Aliquots of cells were 
also removed from the culture each day and grown in the absence of selection until the cell 
viability reached at least 90 %. Then, the volumetric productivity of each cell pool was 
evaluated in a 4-day batch culture that was inoculated at 3 x 105 cells/mL in the absence of 
selection. The volumetric TNFR:Fc productivity of the cell pools increased with the 
duration of selection up to day 5 and then remained at a similar level for selection durations 
up to 10 days (Fig. 3.1A). However, the cell viability in the selected cell population reached 
>90 % only after 8 days of selection (Fig. 3.1A). For this reason, we chose a selection 
duration of 10 days for all future experiments.  
The timing of the start of selection with puromycin was investigated next. The cells were 
co-transfected with pMPIG-TNFR:Fc and pmPBase as described above. At 1, 2 or 3 days 
post-transfection, selection was started with 10 µg/mL puromycin and was continued for a 
total of 10 days. The TNFR:Fc productivity of the three resulting cell pools was measured 
in 4-day batch cultures that were inoculated at 3 x 105 cells/mL. All three cell pools 
produced the same level of TNFR:Fc (Fig. 3.1B), indicating that selection could begin from 
1 – 3 days post-transfection for cell pool generation. We arbitrarily chose 2 days post-





      
Figure 3.1. Investigation of the duration and start of selection for cell pool generation. Cells were co-
transfected in duplicate with pMPIG-TNFR:Fc and pmPBase at a ratio of 9:1 (w/w). (A) The cells were 
selected in 10 µg/mL puromycin for 1 – 10 days as indicated. The cell viability of the populations under 
selection was measured daily (black line). Each day, cells were removed from the selected culture and grown 
in the absence of selection for up to 10 days. The volumetric TNFR:Fc productivity of each cell pool was 
measured by ELISA at the end of a 4-day batch culture (bars). (B) The cells were grown in 10 µg/mL 
puromycin starting at day 1, 2 or 3 post-transfection and then selected for 10 days. The volumetric 
productivity of the pools was analyzed from 4-day batch cultures using ELISA.  
3.2.2. Optimization of donor:helper vector ratio for efficient PB-mediated cell pool 
generation 
Different ratios of donor and helper plasmids were tested to find the optimal condition for 
the efficient generation of PB-mediated clones. Cell pools expressing TNFR:Fc were 
generated by co-transfection with different amounts of the helper vector pmPBase ranging 
from 0.01 % to 50 % of the total transfected DNA. The donor vector pMP-PB-TNFR:Fc 
was used to complete the total transfected DNA to 100%. A control transfection with donor 
pDNA alone in the absence of any helper plasmid was also performed. The resulting cell 
pools were subjected to a 4-day batch culture. 
A dose-dependent increase in TNFR:Fc productivity was observed as an increasing amount 
of pmPBase was transfected (Fig. 3.2). The volumetric productivity remained constant for 
transfection conditions with ≥1 % of pmPBase. The productivity of the PB-mediated cell 
pools was 4-5 fold higher than for the cell pool generated by conventional transfection (100 





effectively generate PB transposon – mediated cell pools. However, there was a 2-fold 
increase in cell pool productivity when 0.1 % pmPBase was used as compared to 1 % (Fig. 
3.2). To avoid transfecting under sensitive conditions where the change of external 
parameters (e.g. media) may affect DNA uptake, we chose to use 10 % of helper plasmid 
for future experiments. 
 
Figure 3.2. Optimization of the amount of helper plasmid for cell pool generation. Cell pools expressing 
TNFR:Fc were generated by transfecting cells with different amounts of pmPBase, ranging from 0 % to 50 
% of the total amount of DNA. The donor vector was added at 100 % to 50% of the total DNA. Each 
transfection was conducted in duplicate and each ELISA measurement was performed in duplicate. Thus, the 
error bars represent the standard deviation from 4 different measurements. The TNFR:Fc expression levels 
of the cell pools were analyzed from 4-day batch cultures. 
3.2.3. Generation of PB-mediated cell pools by selection with different antibiotics 
To determine if cell pools could be generated by selection with antibiotics other than 
puromycin, we constructed a family of TNFR:Fc expression vectors for selection in 
puromycin (pMPPB-TNFR:Fc), blasticidin (pSBBPB-TNFR:Fc), hygromycin B 
(pSBHPB-TNFR:Fc), and zeocin (pSBZPB-TNFR:Fc) as described in Chapter 2. Cells 
were co-transfected with one of these donor vectors and pmPBase at a ratio of 9:1 (w/w). 
As a control, cell pools were also generated by conventional plasmid transfection by 
replacing pmPBase with filler DNA. For each antibiotic, a range of concentrations was 
tested to identify the optimal conditions for cell pool generation. Since the selection agents 





cell viability increased to more than 90 %. This occurred after 7 – 14 days of selection for 
the four antibiotics tested (data not shown).  
The volumetric TNFR:Fc productivity of each cell pool was measured at the end of a 4-day 
batch culture as previously described. For each antibiotic, the maximum TNFR:Fc level for 
the pools generated with the PB system was 3 – 4 times higher than the maximum level 
observed in the control cell pools (Fig. 3.3 A-D). In the presence of puromycin, 
concentrations of 5 – 10 µg/mL were found to be optimal for protein production (Fig. 3.3A). 
The optimal concentrations of blasticidin (10 µg/mL), hygromycin B (200 µg/mL), and 
zeocin (50 µg/mL) also resulted in cell pools with volumetric TNFR:Fc productivities of 
80 – 90 mg/L (Fig. 3.3 B-D). These findings demonstrated that cell pools could be 
generated with similar volumetric productivities in the presence of different selection 
agents. However, we observed a decrease in the volumetric productivities of PB-mediated 
















Figure 3.3. Volumetric TNFR:Fc productivity of cell pools generated in the presence of different 
antibiotics. The cells were co-transfected with either (A) pMP-PB-TNFR:Fc, (B) pSB-BPB-TNFR:Fc, (C) 
pSB-HPB-TNFR:Fc, or (D) pSB-ZPB-TNFR:Fc and either pmPBase (+PBase) or filler DNA (-PBase) at a 
9:1 ratio (w/w). Transfected cells were selected in different concentrations of (A) puromycin, (B) blasticidin, 
(C) hygromycin B, or (D) zeocin. Cells were maintained under selective pressure until the cell viability 
reached 90% or more. The cells were then grown in the absence of selection for 10-14 days and used to 
inoculate 4-day batch cultures for the analysis of TNFR:Fc production by ELISA. The cells (-PBase) selected 






3.2.4. Evaluation of transposition efficiency of PB system 
Cells were co-transfected with pMPIG-TNFR:Fc and pmPBase at a ratio of 9:1 (w/w) to 
generate cell pools labeled PB. The control transfection was performed in parallel by 
replacing pmPBase with filler DNA to generate cell pools labeled TX. On day 2 post 
transfection, one set of transfected cells was placed under selective pressure with 10 µg/mL 
puromycin for 10 days, as per the protocol described in Chapter 2 (Fig. 2.2), resulting in 
cell pools labeled TX(2) and PB(2). To assess the integration efficiency of the transposon 
system in the absence of selection pressure, cell pools were generated by allowing the 
transfected cells to grow in the absence of selection until the episomal DNA was lost before 
applying the selective pressure. For this purpose, another set of transfected cells labeled 
TX(0) and PB(0) was maintained by regular subculture in the absence of selection and 
analyzed daily for EGFP-specific fluorescence using flow cytometry. These unselected cell 
pools were doubling regularly (data not shown). At 10 days post-transfection, the 
percentage of EGFP-positive cells had stabilized at ~20 % in the case of PB-mediated 
transfections and at ~3 % for transfections without PB, indicating the complete loss of 
transient EGFP expression in these cell pools (Fig. 3.4A). We hypothesized that loss of 
transient EGFP expression in the cell pools suggested the loss of episomal DNA in the 
cells. At 10 days post-transfection, the cell pools TX(0) and PB(0) were placed under 
selective pressure with puromycin (10 µg/mL) for 10 days to generate pools TX(10) and 
PB(10). The cell pools TX(0) and PB(0) were continued to be cultivated in the absence of 
selection for 30 days, with regular analyses of EGFP-specific fluorescence. In addition to 
the ~5 fold higher percentage of EGFP-positive cells in the PB(0) cell pool compared to 
TX(0), the mean EGFP expression (RFU) for PB(0) was also about 4-5 fold higher than for 
TX(0), once transient EGFP expression was terminated.  
The cell pools generated with (PB) and without (TX) the use of transposon systems showed 
different viability trends when placed under selection starting from day 2 or day 10 (Fig 
3.4B, C). The viability of TX(10) decreased to 10 % while that of TX(2) decreased to ~50 
% (Fig. 3.4B). In contrast, irrespective of starting selection before (PB(2)) or after (PB(10)) 
the loss of transient EGFP expression, the cell pools had very similar patterns of cell 






             
Figure 3.4. Viability and volumetric productivity of cell pools under different selection conditions. Cell 
pools were generated with pMPIG-TNFR:Fc and pmPBase (PB) or pMPIG-TNFR:Fc and filler DNA (TX) 
at a ratio 9:1 (w/w). Cell pools were placed under selection pressure on day 2 (TX(2) and PB(2)) or on day 
10 (TX(10) and PB(10)) post-transfection. As a control, one set of transfections was cultivated in the absence 
of selection (TX(0) and PB(0)). (A) The percentage of EGFP-positive cells (filled markers) and the mean 
fluorescence intensity (empty markers), represented as relative fluorescence units (RFU), in TX(0) and PB(0) 
cell pools was determined at the times indicated by flow cytometry. The viabilty of the cell pools transfected 
in the absence (B) and presence (C) of the PB system was assessed during the selection phase. (D) The 
volumetric productivity of different cell pools were determined by ELISA at the end of 4-day batch cultures.   
The expression level of the PB(2) cell pools was 5-fold higher than for the TX(2) cell pools 
(Fig. 3.4D). Although the TX(2) and TX(10) cell pools had similar volumetric 
productivities, the PB(10) cell pools produced less TNFR:Fc than did the PB(2) cell pools 
(Fig. 3.4D). However, it is important to note that the TX(10) cell pool was generated from 





3.2.5. Evaluation of protein production and stability of cell pools in 14-day batch 
cultures 
To show the reproducibility of cell pool generation and to study the productivity and 
viability in a production scenario (14-day culture), cell pools co-expressing TNFR:Fc and 
EGFP were generated from five independent transfections in which cells were co-
transfected with pMPIG-TNFR:Fc and pmPBase at a 9:1 ratio (w:w). Cell pools were 
recovered by selection with puromycin (10 µg/mL) for 10 days starting on day 2 post-
transfection. The volumetric TNFR:Fc productivity of each pool was evaluated in a 14-day 
biphasic batch culture with a temperature shift to 31 °C from 37 °C on day 4 post-
inoculation. The cell density, cell viability, and volumetric TNFR-Fc productivity of the 
cultures were analyzed daily. All the cell pools had similar cell density and cell viability 
profiles, with the maximum cell density reaching 7 – 8 x 106 cells/mL at day 7 or 8 post-
inoculation (Fig. 3.5A). The volumetric TNFR:Fc productivities reached 350 – 550 mg/L 
by day 14 post-inoculation (Fig. 3.5B). 
To assess the stability of TNFR:Fc production over time, the cell pools were maintained in 
the absence of selection for an additional 2 months. At the end of each month, 14-day batch 
cultures of 100 mL were inoculated with each cell pool. The cell density and viability trends 
of the cell pools were similar to those observed at the 1-month time point (data not shown). 
Over the 3-month cultivation period, the volumetric TNFR:Fc yield declined only in pool 
2 (Fig. 3.5C). For the other four cell pools, the productivity was found to be stable for 3 








      
 
Figure 3.5. Cell growth and TNFR:Fc production by cell pools. Cell pools were generated from five 
independent co-transfections performed on different days with pMPIG-TNFR:Fc and pmPBase at a ratio of 
9:1 (w/w). Selection was performed for 10 days in 10 µg/mL puromycin to generate cell pools numbered 1 – 
5. The cell pools were grown in 14-day batch cultures at a volume of 100 mL in 500-mL cylindrical glass 
bottles. (A) The live cell density and cell viability were measured daily by the Trypan Blue exclusion method 
using a hemocytometer. (B) Volumetric TNFR:Fc productivities were measured daily by ELISA. (C) The 
volumetric TNFR:Fc productivities of each pool were compiled from 14-day cultures after 1, 2, and 3 months 






3.3. Discussion  
Long genetic selection durations, low volumetric protein yields, and loss of protein 
productivity over time in culture have typically been the key issues limiting the use of cell 
pools as a protein production method (Fan et al. 2013; Ye et al. 2010). However, with 
improved expression vectors and the enrichment of the recombinant cell population by 
fluorescence-activated cell sorting (FACS), it has been possible to generate cell pools 
expressing up to 1 g/L from a 2-week fed-batch process (Fan et al. 2013; Ye et al. 2010). 
However, the productivity of the cell pools was not stable over time in the absence of 
selection as a decrease in volumetric productivity of 40% per week was observed (Ye et al. 
2010). Moreover, the entire process from transfection to protein production took a total of 
about 8 weeks. Hence, there is a need for an improved method to rapidly generate high-
yielding cell pools whose productivity is constant over time.  
Here we showed that PB-mediated cell pools can be generated with a selection duration of 
5-10 days, resulting in cell pools with productivities 3-4 times higher than those generated 
by conventional plasmid transfection. Furthermore, the addition of a selection agent on 1, 
2 or 3 days post-transfection did not affect the growth or productivity of the cell pools, 
indicating that transposition was a rapid event that occurred within 24 h of transfection. We 
also compared the use of different antibiotics for the selection of cell pools. Irrespective of 
the selection agent, the maximum protein yields were similar and were 3-4 fold better than 
the cell pools resulting from conventional plasmid transfection. However, we observed a 
decrease in the volumetric productivities of PB-mediated cell pools at the highest 
concentrations of puromycin and hygromycin B tested (Fig. 3.3A, C). These cell pools had 
slower growth rates than the other cell pools, and this may have resulted in reduced protein 
productivities (data not shown). Puromycin and hygromycin B are known to function by 
inhibiting protein synthesis (Darken 1964; Gonzalez et al. 1978). This mode of action may 
also have contributed to the decrease in protein productivity at the higher antibiotic 






Our results from the evaluation of the integration efficiency of the PB transposon 
corroborates our previously published results (Matasci et al. 2011). We observed that (1) 
~20 % cells remained EGFP-positive in the absence of selection for the PB system in 
contrast to only ~3 % for conventional plasmid transfection and (2) the mean EGFP 
expression level was 4-5 fold higher for the PB system in comparison to conventional 
transfection (Fig. 3.4A). These results not only demonstrate the superior integration 
efficiency but also the superior transgene expression of transgenes transposed into the host 
genome in contrast to the integration of transfected plasmid DNA by recombination. We 
propose that this advantage could be utilized towards generation of “selection-free” clonal 
cell lines by coupling with other technologies such as FACS, using fluorescent-labeled 
antibodies, for enriching the recombinant cell population. Also, many high-yielding cell 
lines recovered after selection are known lose their expression once the selection pressure 
is removed (Chusainow et al. 2009; Kim et al. 2011). However, we speculate that 
‘selection-free’ clonal cell lines would be more stable since they never encountered any 
selection pressure and the integrations have occurred independent of selection.  
It is generally agreed that plasmid DNA integration into the genome is independent of 
selection pressure, and selection is only used to eliminate non-recombinant cells. Thus, loss 
of integrated transgenes or epigenetic silencing of the transgenes in TX(0) during growth, 
prior to the start of selection on day 10 post-transfection, are the probable causes of the 
decrease of the viability in cell pools TX(10) to ~10 % compared to the ~50 % in TX(2). 
Loss of integrated transgenes has been previously reported in recombinant cells grown in 
the absence of selection, while this is not the case for recombinant cells grown in the 
presence of selection (Weidle et al. 1988). In contrast to above observations, PB(2) and 
PB(10) had very similar viability trends after initiation of selection, with the minimum level 
reaching ~50 % (Fig. 3.3C). This implied that a similar percentage of cells was resistant to 
selection pressure, reiterating the evidence that PB-mediated integrations are rapid and 
stable events. 
We have shown PB-mediated cell pool generation to be a rapid and simple technology that 
can reproducibly yield cell pools with a high level of protein productivity which can be 












Comprehensive Study of PB, Tol2 and SB 













Several studies have compared the activities and integration profiles of PiggyBac (PB), 
Tol2 and Sleeping Beauty (SB) transposon systems in human cells, mainly focusing on 
applications in gene therapy (Grabundzija et al. 2010; Huang et al. 2010; Meir et al. 2011; 
Sharma et al. 2012; Wu et al. 2006). Recently the PB transposon system has been 
recognized for its potential in the generation of stable pools and clones for recombinant 
protein production (Alattia et al. 2013; Kahlig et al. 2009; Li et al. 2013; Matasci et al. 
2011). However, to our knowledge, these three transposon systems have not been compared 
side by side for their application in recombinant protein production in CHO cells.  
In this work, the PB, Tol2 and SB transposon systems were used for the generation of stable 
CHO pools and clones. The mouse-codon-optimized PB transposase gene (mPB), a 
mammalian codon-optimized Tol2 transposase, and the hyperactive SB transposase 
(SB100X) were used to establish recombinant cell pools (Cadinanos and Bradley 2007; 
Mates et al. 2009). The cell pools were generated using the standard protocol described in 
Chapter 2 (Fig. 2.2).  
The amount of donor and helper vectors required for efficient transposition was estimated 
for the three transposon systems. The transposition efficiencies were analyzed based on the 
number of transposon-mediated integrations versus the number of integrations resulting 
from DNA recombination and the percentage of recombinant cells resulting from 
transfection in the absence of selection. The number of integrated transgenes and the 
relative level of transgene mRNA transcription in each cell pool were also determined. 
Finally, cell pools and clones were subjected to simple fed-batch production processes from 
which the volumetric protein yield was measured. Our data demonstrates the efficacy and 
robustness of protein expression methods in which the use of transposon-mediated 
transgenesis is combined with the pool-based rapid generation of high-expressing 






4.2.1. Generation of cell pools with three transposon systems using various amounts 
 of helper vector  
Different ratios of donor and helper vectors were tested to find the optimal conditions for 
the generation of cell pools expressing TNFR:Fc. In short, the donor plasmids expressing 
TNFR:Fc (pSBP-PB-TNFR:Fc, pSBP-Tol2-TNFR:Fc or pSBP-SB-TNFR:Fc) were co-
transfected with their respective helper plasmids (pmPBase, pmTol2ase, or pSBase, 
respectively). The amount of helper vector ranged from 0.01 – 50 % of the total DNA 
transfected. Control transfections with each donor vector alone (100 % of the total DNA) 
were also performed. The pools were generated as described in Chapter 2 (Fig. 2.2). In 
short, the cells were placed under puromycin (10 µg/mL) selection for 10 days, from day 2 
to day 12 post-transfection. Once generated, each cell pool was grown in the absence of 
selection in cultures inoculated at 0.3 x 106 cells/mL. At day 4 post-inoculation, the 
volumetric TNFR:Fc production of each cell pool was measured by ELISA.  
For all three transposon systems, the TNFR:Fc productivity increased as the amount of 
helper vector increased until a plateau was achieved (Fig. 4.1A). In the case of the PB 
system, the highest productivity levels were achieved with 1 - 50 % pmPBase. For the SB 
system, the highest productivity levels were obtained following transfection with 10 - 50 
% pSBase (Fig. 4.1A). For the Tol2 system, the highest productivity levels were observed 
following transfection with 10 - 30 % pTol2 (Fig. 4.1A). However, the TNFR:Fc 
productivity of the pools decreased from 90 mg/L to 60 mg/L when the amount of 
transfected Tol2ase was increased to 50 %. All three transposon systems generated cell 
pools expressing similar volumetric productivities under optimal conditions for the ratio of 
donor to helper vector. These values were up to 5-fold higher than the productivities of cell 









Figure 4.1. Analysis of cell pools generated with various amounts of donor and helper vectors. For each 
transposon system, cells were co-transfected with different amounts of helper vector, ranging from 0 – 50 % 
of the total DNA. For each transfection, the donor vector accounted for the remainder of the total DNA. Cell 
pools were generated by selecting with puromycin (10 µg/mL) for 10 days. For each cell pool, the TNFR:Fc 
yield was determined by ELISA at the end of 4-day batch culture (A). The TNFR:Fc and bla gene copy 
number per cell was determined by RT-qPCR on the cell pools generated with the (B) PB system, (C) Tol2 
system, and (D) SB system. Each transfection was performed in duplicate, and each ELISA and RT-qPCR 
was performed in duplicate. Thus, each error bars represents the standard deviation from 4 different 
measurements. 
Next, the average transgene copy number per cell was determined for each cell pool by RT-
qPCR. On the donor plasmid, the inverted repeats of the transposon allow incorporation of 
both the TNFR:Fc gene and the pac gene but not the bla gene in the artificial transposon 
(Fig. 2.1A). Thus, the latter was not transposed into the CHO genome, but it could have 





copy numbers of the TNFR:Fc and bla genes corresponds to the average number of 
integration events that occurred by transposition in each cell pool. In PB-mediated cell 
pools, the average number of copies per cell of the TNFR:Fc gene was similar for all 
conditions (Fig. 4.1B). However, the number of copies of the bla gene decreased as the 
amount of transfected pmPBase increased (Fig. 4.1B). Thus, the number of transposon-
mediated integrations increased as the amount of helper vector increased such that with 10 
% or more pmPBase, about two-thirds of the integration events were mediated by 
transposition. Surprisingly, in the case of Tol2-mediated cell pools, the copy number values 
of the TNFR:Fc and bla genes were similar in all conditions except in cell pools transfected 
with 10 % pmTol2ase, implying most integrations were occurring by non-homologous 
recombination in cells transfected with this transposon system (Fig. 4.1C). In the presence 
of 10 % pmTol2ase, about 40 % of the integration events were transposon-mediated (Fig. 
4.1C). In the case of SB-mediated cell pools, the copy number of the bla gene decreased as 
the amount of pSBase transfected increased (Fig. 4.1D). For both PB- and SB-mediated 
cell pools, at best 60 – 70 % of the integration events were transposon-mediated at best. 
These results indicated a higher transposition efficiency of these two transposon systems 
as compared to the Tol2 system. Based on these results, we concluded that the optimal ratio 
of donor to helper vector is 9:1 (w/w) for all three transposons. 
4.2.2. Generation of cell pools with three transposon systems using various amounts 
 of donor vector  
Cells were transfected with different amounts of donor vector, ranging from 5 – 90 % of 
the total DNA, while maintaining the amount of helper pDNA at 10 % of the total DNA. 
Cells were co-transfected with various amounts of a donor vector expressing EGFP (pMP-
PB-EGFP, pSB-PTol2-EGFP, or pSB-PSB-EGFP) and a helper vector (pmPBase, 
pmTol2ase or pSBase, respectively). The total amount of transfected DNA was kept 
constant by using filler DNA to replace some of the donor vector. Cell pools were also 
generated by transfection with each donor vector alone. Pools were generated by selecting 
with puromycin (10 µg/mL) for 10 days as described in Chapter 2. The % of EGFP-positive 





The co-transfections with the PB system resulted in >99 % EGFP-positive cells even when 
only 5 % of total DNA was from the donor vector (Fig. 4.2A). In the transfection with the 
donor vector alone, 90 % of the cells were EGFP-positive (Fig. 4.2A). In contrast, only 
about 60 % of the cells were EGFP-positive in cell pools resulting from transfection with 
SB or Tol2 donor vector alone (Fig. 4.2A). For both the SB and Tol2 systems, transfections 
with donor vector amounts of 25 % and more resulted in cell pools with similar levels of 
EGFP-positive cells (Fig. 4.2A). However, this was 20 – 30 % lower than the maximum 
level of EGFP-positive cells in the PB-mediated cell pools. For all three transposon 
systems, the EGFP expression levels of cell pools resulting from transfections with 25 – 90 
% of the donor plasmid were similar (Fig. 4.2B). However, the EGFP levels were 40 % 
lower for cell pools resulting from transfections with the Tol2 and SB transposon systems 
as compared to the EGFP levels of the PB-mediated cell pools (Fig. 4.2B).  
  
Figure 4.2. Analysis of EGFP expression by transposon-mediated cell pools generated with various 
amounts of donor plasmid. Cells were co-transfected with different amounts of donor vector (pMP-PB-
EGFP, pSB-PTol2-EGFP, or pSB-PSB-EGFP), ranging from 5 % to 90 % of the total DNA, and a helper 
vector (pmPBase, pmTol2ase or pSBase, respectively) at 10% of the total DNA. The total amount of 
transfected DNA was kept constant by addition of filler DNA. Cell pools were generated by selecting with 
puromycin (10 µg/mL) for 10 days. Each transfection was conducted in duplicate and each measurement was 
performed in duplicate. Thus, the error bars represent the standard deviation from 4 different measurements. 
The % of EGFP-positive cells (A) and the relative fluorescence units (RFU) (B) in the cell pools were 





4.2.3. Analysis of transposition efficiency in the absence of selection  
Cells were co-transfected with a donor plasmid expressing EGFP (pMP-PB-EGFP, pSBP-
Tol2-EGFP or pSBP-SB-EGFP) and helper plasmids (pmPBase, pmTol2ase, or pSBase, 
respectively) at a ratio of 9:1 (w/w). Cell were also transfected with the donor vector and 
filler DNA at a 9:1 ratio (w/w). The cells were cultivated in the absence of selective 
pressure with passage every 3-4 days and analyzed regularly for EGFP-specific 
fluorescence by flow cytometry during a cultivation period of 30 days. The efficiency of 
recombinant cell generation was then estimated from the percentage of EGFP-positive cells 
in the population at 30 days post-transfection, a sufficiently long cultivation time in the 
absence of selection to eliminate any transiently expressed EGFP.  
For all the conditions tested, the percentage of EGFP-positive cells gradually decreased 
during the first 10 – 12 days post-transfection and then stabilized at defined levels (Fig. 
4.3). All three of the control transfections with donor vector alone had about 1 % EGFP-
positive cells, while cells transfected with the PB and SB systems stabilized at 22 % and 
14 % EGFP-positive cells, respectively (Fig. 4.3). For the cells transfected with the Tol2 
system, only about 1 % of cells were EGFP-positive (Fig. 4.3). These results showed that 
the PB system was the best of the three transposon systems in terms of generating 







Figure 4.3. Determination of the efficiency of recombinant cell generation with the PB, Tol2 and SB 
transposon systems. Cells were co-transfected in duplicate with a donor vector expressing EGFP (pMP-PB-
EGFP, pSBP-Tol2-EGFP or pSBP-SB-EGFP) and a helper vector (pmPBase, pmTol2ase, or pSBase, 
respectively) for the respective transposon system (+PBase, +Tol2ase, +SBase) at a 9:1 ratio (w/w). 
Transfections were also conducted with each donor vector alone (-PBase, -Tol2ase, -SBase). The percentage 
of EGFP-positive cells in each culture was determined by flow cytometry at the times indicated. The results 
for each condition are represented as average values of two independent transfections. 
4.2.4. Protein productivities of cell pools generated with each transposon system  
Cell pools were generated with the donor vectors pSBP-PB-TNFR:Fc, pSBP-Tol2-
TNFR:Fc, pSBP-SB-TNFR:Fc in the presence and absence of the respective helper vector 
pmPBase, pmTol2ase, or pSBase. In addition to the control transfections in the absence of 
helper vector, we constructed an expression vector without terminal repeats (pMP-
TNFR:Fc).  The cell pools generated from transfections with pMP-TNFR:Fc alone were 
termed “Non-TP” cell pools.   
 For each cell pool, the volumetric protein productivity was analyzed at the end of 4-day 
batch cultures. Overall, all transposon-mediated cell pools had volumetric TNFR:Fc yields 
above 80 mg/L (Fig. 4.4) as was described above (Fig. 4.1A). In addition, the protein yields 
from “Non-TP” cell pools were 2-3 fold lower than the yields from cell pools generated 
with donor vector alone (Fig 4.4). These results showed that the three transposon systems 
were able to generate cell pools with similar volumetric productivities, which was ~9 fold 





repeats in the donor plasmids played a role in improving the protein yields. Henceforth, 
cell pools generated with pMP-TNFR:Fc alone were used as a control.  
 
Figure 4.4. Volumetric productivity of cell pools generated with different transposon systems. Cells 
were transfected as in Fig. 4.3 with different donor vectors, with (+TPase cell pools) and without (-TPase cell 
pools) the respective helper vectors (PB, Tol2, or SB). Another transfection was performed with pMP-
TNFR:Fc alone.  This expression vector did not have ITRs for any transposon system (Non-TP cell pools). 
Cell pools were generated by selecting with puromycin (10 µg/mL) for 10 days. The volumetric productivities 
were measured by ELISA at the end of 4-day batch cultures. Each transfection was conducted in duplicate 
and each measurement was performed in duplicate. Thus, the error bars represent the standard deviation from 
4 different measurements. 
4.2.5. Transgene mRNA analyses of transposon mediate cell pools  
For the transposition-mediated cell pools and the Non-TP cell pools described in the 
previous section, the average integrated TNFR:Fc gene copy number and the relative 
amount of its mRNA were determined. RT-qPCR was performed on total cellular DNA 
from the cell pools as described in Chapter 2. The average transgene copy number was 
similar for each of the cell pools generated with a transposon system but lower than the 
transgene copy number for the Non-TP cell pools (Fig. 4.5A).  RT-qPCR was also used to 
determine the relative levels of transgene mRNA.  The level of TNFR:Fc mRNA was 
similar for the cell pools generated with a transposon system (Fig. 4.5B).  The relative 
transgene mRNA levels were about 4-fold higher for these cell pools than for the Non-TP 





not as well-transcribed in the Non-TP cell pools as they were in the transposon-mediated 
cell pools. 
  
Figure 4.5. Integrated transgene copy number and transgene mRNA levels in cell pools generated with 
and without transposition. (A) The TNFR:Fc gene copy number for cell pools generated with transposition 
(PB, Tol2, SB) and without transposition (Non-TP) was determined by RT-qPCR. (B) The TNFR:Fc gene 
transcription levels were quantified by qRT-PCR and normalized to the level of cellular β-actin mRNA in 
CHO cells. The error bars represent the standard deviations from 4 measurements as each culture and 
analytical measurement was performed in duplicate. 
4.2.6. Analysis of the stability of protein production in cell pools 
It has been shown that the protein production levels of CHO cell pools can decline at a rate 
of 40 % per week when grown in the absence of selection (Ye et al. 2010). This represents 
a severe disadvantage for the production of recombinant proteins from cell pools, 
particularly if repeated productions from the same culture are performed sequentially. 
Hence, the TNFR:Fc productivity of cell pools generated with different transposons (pools 
PB, Tol2, and SB) and those generated by conventional transfection (Non-TP), as described 
in Section 4.2.4, were cultivated in the absence of selection for up to 3 months. The 
productivity of each cell pool was determined periodically at the end of 4-day batch cultures 
inoculated at 0.3 x 106 cells/mL. The volumetric productivity of all the transposon-based 
cell pools gradually declined to about 50 % of the initial level over a period of 2 months 
and then remained constant (Fig. 4.6). Surprisingly, the volumetric productivity of the Non-





of the transposon-mediated cell pools were 3 – 4 fold higher than that of the control cell 
pools at the end of the stability studies. 
 
Figure 4.6. Analysis of the volumetric productivity of cell pools over time in the absence of selection. 
Cell pools were generated with (PB, Tol2, SB) and without (Non-TP) transposition as indicated in Chapter 
2. After selection in puromycin, the cell pools were grown in the absence of selection pressure for 3 months. 
The volumetric productivity was determined by ELISA at the end of 4-day batch cultures at the times 
indicated. 
4.2.7. Analysis of clonal cell lines derived from cell pools 
About 100 clonal cell lines were generated by limiting dilution from cell pools generated 
with one of the three transposons and from the control cell pools. For each clonal cell line, 
the volumetric TNFR:Fc productivity was measured at the end of a 4-day batch culture by 
ELISA. The results showed that on average, the cell lines generated with one of the three 
transposons had higher productivities than did the cell lines generated by conventional 
plasmid transfection (Fig. 4.7A). The distribution of the volumetric productivities of the 
cell lines generated with each of the transposons was similar, but the average productivity 
was the highest for the cell lines generated with the SB system (Fig. 4.7A). The mean 
TNFR:Fc level of the cell lines resulting from conventional plasmid transfection (Non-TP) 
was about 1.5 mg/L, whereas it was about 40 mg/L for the cell lines generated with a 
transposon. About 95 % of the Non-TP cell lines produced less than 1 mg/L TNFR:Fc. For 





10 – 15 % of the transposon-mediated cell lines had volumetric productivities over 100 
mg/L. 
From each set of cell lines, the two with the highest TNFR:Fc productivity were chosen for 
further studies. The 8 cell lines were cultivated in the absence of selection for over 4 
months, and the volumetric productivity was measured monthly from 4-day batch cultures. 
The volumetric productivity was constant over 4 months for each of the transposon-
mediated cell lines (Fig. 4.7B). However, one of the two cell lines generated by 
conventional plasmid transfection (Non-TP1) exhibited reduced productivity with time in 
culture (Fig. 4.7B). The specific productivities (Qp) of all the cell lines were calculated 
based on data from 4-day batch cultures. The results show that the Qp of the transposon-
derived cell lines ranged from 17 – 23 pg/cell/day while those derived by conventional 
plasmid transfection each had a Qp less than 5 pg/cell/day (Fig. 4.7B).  
    
Figure 4.7. Analysis of clonal cell lines generated with different transposons. From each cell pool 
generated with a transposon (PB, Tol2, and SB) or without (Non-TP), 100 cell lines were generated by 
limiting dilution. (A) The volumetric TNFR:Fc productivity of each cell line was measured in a 4-day batch 
culture by ELISA. Each symbol on the plot represents the TNFR:Fc productivity of one cell line. The 
horizontal bars represent the mean of TNFR:Fc production for each condition. (B) The two highest producers 
of the 100 cells lines from Non-TP (Non-TP1, Non-TP2), PB (PB1, PB2), Tol2 (Tol21, Tol22) and SB (SB1, 
SB2) cell pools were chosen for further analysis. The eight cell lines were cultivated for 4 months in the 
absence of selection, and the volumetric productivities were analyzed monthly at the end of 4-day batch 
cultures. The cell-specific productivity (Qp) of each cell line was measured in a 4-day batch culture 





4.2.8. Expression level analysis from a fed-batch culture for cell lines and pools  
The cell pools generated by using PB, Tol2 and SB transposition and by conventional 
transfection (Non-TP) were subjected to a simple non-optimized fed-batch culture of 2 
weeks that included a temperature shift to 31°C at day 3 post-inoculation. The transposon-
mediated pools resulted in TNFR:Fc productivities of 800-900 mg/L whereas the cell pool 
resulting from conventional plasmid transfection produced only about 130 mg/L (Fig. 
4.8A). The top two TNFR:Fc-producing cell lines from each condition as described in 
Section 4.2.7 were also subjected to the same fed-batch cultivation conditions. All 
transposon-generated cell lines produced from 1.3 to 1.5 g/L, whereas the two Non-TP cell 
lines produced about 500 mg/L each (Fig. 4.8B).  
    
Figure 4.8. Volumetric productivities of fed-batch cultures of cell pools and cell lines. The cell pools (A) 
and cell lines (B), as described in Figures 4.4 and 4.7B, respectively, were subjected to a 14-day fed batch 
culture. Each cell pool and cell line was inoculated at a density of 0.5 x 106 cells/mL in a 5 mL volume in a 
TS50. On day 3 post-inoculation, the cultures were fed with 3 g/L glucose and 1.5 g/L essential and non-
essential amino acids and treated with 0.25 % dimethyl acetamide (DMA). The cultures were incubated for 
3 days at 37 °C and then at 31 °C for 11 days. The volumetric TNFR:Fc productivity was then measured by 
ELISA. The error bars represent the standard deviation from 4 measurements as each culture and analytical 






4.3. Discussion  
We investigated the use of PB, Tol2 and SB transposon systems for the rapid generation of 
cell pools for recombinant protein production using CHO-DG44 cells. Under optimized 
conditions, the pools generated with each transposon system showed similar volumetric 
protein productivities, at values 3 – 4 fold higher than the pools generated using the donor 
plasmid alone, and about 9 fold higher than the pools generated with a donor plasmid 
without the inverted repeats of the transposon.  Using the three transposon systems, we 
were able to generate cell pools with TNFR:Fc expression levels of 800-900 mg/L and cell 
lines with expression levels of 1.3-1.5 g/L with a simple, non-optimized fed-batch process. 
In contrast, PB-derived cell pools expressing EGFP had ~20 % more EGFP-positive cells 
and ~40 % higher EGFP expression levels than the cell pools generated using the Tol2 or 
SB transposon systems. 
We observed some differences among the transposon systems tested. The performance of 
the Tol2 transposon system in terms of the percentage of recombinant cells per transfection 
and the percentage of transgene integrations by transposition rather than DNA 
recombination were inferior to those of the PB and SB transposon systems. The transgene 
copy number analysis showed that transgene integration by DNA recombination in cell 
pools following transfection with a transposon system was frequent. In PB and SB 
transposon systems, 60 – 70 % of the transgene integrations resulted from transposition 
under the optimal transfection conditions. However, only 40 % of the integration events 
were by transposition in cell pools following transfection with the Tol2 system. In spite of 
having 60 % of the transgene integrations by DNA recombination, the volumetric 
productivities of the Tol2-mediated cell pools were the same as those of PB- or SB-
mediated cell pools.  
With an increase in the amount of pmTol2ase transfected, both the productivity of the pools 
and the number of transposon-mediated integrations declined. This may indicate the 
occurrence of the discussed phenomenon of OPI, the phenomenon that limits the 
transposition activity at increasing transposase levels (Grabundzija et al. 2010). On the 





appear to exhibit OPI (Grabundzija et al. 2010; Wilson et al. 2007; Wu et al. 2006). The 
decline in the volumetric productivity in Tol2-mediated pools as the amount of pmTol2ase 
increased may also have been due to integration of the transposase gene which could 
potentially mediate excision of the integrated transgene.  
The PB and SB transposon systems demonstrated a higher percentage of stable recombinant 
cells in a transfected population compared to the Tol2 system or to conventional plasmid 
transfection. Efforts have recently been made to enhance the transposition efficiency for 
PB and SB, resulting in very effective transposases like the hyperactive PBase and SB100X 
(Cadinanos and Bradley 2007; Mates et al. 2009; Meir et al. 2013; Yusa et al. 2011). 
However, Tol2 has not been genetically engineered for improved performance. Although 
all the transposase enzymes in this study were codon optimized for mammalian expression, 
we believe that further improvements of transposition efficiency can be obtained by 
modification of the ITRs or by mutagenesis of the respective transposase genes. 
Nevertheless, the protein productivity of cell pools generated using the three transposon 
systems tested was very similar. 
Interestingly, the ITRs of all three TP systems had a slightly positive impact on recombinant 
protein production even in the absence of the transposase. The ITRs mainly consist of 
repeat elements that are AT rich. I propose that, even in the absence of the transposase 
enzyme, these regions of the plasmids will frequently undergo double-strand – single-
strand DNA conversions and thus facilitate integration, possibly even with a preference to 
widely distributed and frequent AT-rich regions in the genome, homologous in sequence 
to the incoming DNA. In support of this hypothesis, it has been reported that the presence 
of sequences of CHO endogenous retroviral origin, when present in transfected plasmids, 
had a positive effect on the average productivity from recombinant clones (Lewis et al. 
2013; Wurm 1994). The probability of such facilitation of integration is high since 
optimized PEI-mediated transfections, as used here, can deliver 40,000 – 100,000 plasmid 
molecules per cell (Backliwal et al. 2008; Rajendra et al. 2012). 
It was shown that the improved protein productivity from transposon-derived cell pools 





TP cell pool. This was surprising since Non-TP pools had a 2-fold higher integrated 
transgene copy number. This strongly supports the notion that integrated transgenes in 
transposon-mediated cell pools were better transcribed than those in Non-TP cell pools. 
This is in agreement with conclusions drawn from previous publications, where it was 
suggested that transposases integrate the transgenes into transcriptionally active regions, 
thereby resulting in higher transcription levels leading to increased productivities (Galvan 
et al. 2009; Grabundzija et al. 2010; Meir et al. 2011; Wilson et al. 2007). 
We observed a gradual decrease in volumetric productivity of the transposon-mediated cell 
pools to about 50 % of their initial levels within 2 months of cultivation in the absence of 
selection. Previously, we generated cell pools with the PB system that were stable for 3 
months in the absence of selection (Chapter 3). However, the lot of the medium was 
changed between the previous studies and those reported here. We suspect that this may 
contribute to the loss in the stability of the productivity of the cell pools. Also, previously 
published results from cell pools showed a decline in protein production of 40 % per week 
in spite of the cell pools being selected by FACS for a high level of fluorescent protein 
expression (Ye et al. 2010). In comparison, the decline observed here was only about 10-
15% per week. It is also important to note that a decline of 15-20% in protein productivity 
over 60 population doublings (about 2 months, assuming a doubling time of 24 hours) is 
typically considered acceptable for commercial cell lines (Wurm, personal 
communication). Therefore, our 12-week assay can be considered sufficient to assess the 
stability of the volumetric productivity in a cell pool. Importantly, even after 2 months, the 
protein productivity of the transposon-derived cell pools was still 4 times higher than the 
Non-TP cell pool.  
Lastly, the average volumetric productivity of cell lines recovered from transposon-derived 
cell pools was higher than that from cell lines recovered from the control cell pools.  Thus, 
the use of the transposon systems allowed a much greater efficiency in the generation of 
highly productive clonal cell lines using CHO-DG44 as the host. This means that a smaller 
number of cell lines would need to be screened to obtain ones with a high level of protein 





used for the generation of cell pools expressing high levels of recombinant protein, with a 










Study of the Three Transposon Systems 
for Cell Pool Generation in Different CHO 











CHO-DG44, CHO-K1 and CHO-S are three of the most commonly used CHO strains in 
the biopharmaceutical industry. Although these strains share a common origin, they are 
known to have different genotypes and phenotypes (Derouazi et al. 2006; Lewis et al. 2013; 
Wurm 2013). To improve the applicability of transposon systems for cell pool and cell line 
generation, we decided to evaluate the use of the PB, Tol2 and SB transposon systems for 
gene delivery in these three CHO strains. The CHO-DG44 cells were isolated in 1983 and 
have been in culture in the LBTC for more than 15 years (Urlaub et al. 1983). The CHO-
K1 cells were suspension-adapted in the LBTC in 2012 from adherent cells obtained from 
the ATCC. The CHO-S cells are suspension-adapted cells that are commercially available 
from Life Technologies.  
The efficiency of the generation of recombinant cells using the three transposon systems in 
the different CHO strains was compared. The transposon-mediated cell pools were 
generated based on the protocol developed for CHO-DG44 cells, and the volumetric 
productivities of the various cell pools were measured. The stability of the volumetric 
productivity over 2 months in the absence of selection was also measured. An analysis of 
average integrated gene copy number was also performed as a way to compare the activity 







5.2.1. Generation of recombinant cells following transfection of three CHO strains 
 with three different transposon systems 
Three different CHO strains were separately co-transfected with three combination of a 
donor plasmid (pMP-PB-IRES-EGFP, pSBP-Tol2-IRES-EGFP or pSBP-SB-IRES-EGFP) 
and a helper plasmid (pmPBase, pmTol2ase, or pSBase, respectively) at the ratio of 9:1 
(w/w). The donor vectors each express the TNFR:Fc and EGFP genes from a bicistronic 
mRNA in which the two genes are separated by the EMCV IRES (Table 2.1). For each 
combination of cell strain and transposon system, a control transfection was performed with 
the donor plasmid and filler DNA at a 9:1 ratio (w/w). The cells were cultivated in the 
absence of selective pressure with passage every 3-4 days and analyzed regularly for EGFP-
specific fluorescence by flow cytometry for 30 days. The efficiency of recombinant cell 
generation was then estimated from the percentage of EGFP-positive cells in the population 
at 30 days post-transfection, a sufficiently long cultivation time to eliminate any transiently 
expressed EGFP from the population. 
For all the conditions tested, the percentage of EGFP-positive cells gradually decreased 
during the first 10–12 days and then remained constant at defined levels (Fig. 5.1 A-C). All 
control transfections with donor vector alone had only about 1% EGFP-positive cells at day 
30, indicating that this percentage of cells in the transfected population were recombinant 
(Fig. 5.1 A-C). The % EGFP-positive cells in transfections using the PB transposon system 
stabilized at 10 – 15 % for all three CHO strains (Fig. 5.1A). For the transfections 
performed with the Tol2 and SB systems, the percentage of EGFP-positive cells stabilized 
at 4 – 7 % and 5 – 20 %, respectively (Fig. 5.1B, C). For the transfections performed with 
the SB transposon system, a higher percentage of EGFP-positive cells was observed using 
CHO-DG44 cells as the host in comparison to the other two CHO strains (Fig. 5.1C). 
Transfections using Tol2 and SB transposon systems showed similar EGFP profiles for 
CHO-K1 and CHO-S cells (Fig. 5.1B, C). For all three transposon systems in all three CHO 








Figure 5.1. Determination of the efficiency of recombinant cell line generation with the three 
transposon systems. Cells were transfected in duplicate with a donor vector (pMP-PB-IRES-EGFP, pSBP-
Tol2-IRES-EGFP or pSBP-SB-IRES-EGFP) and a helper vector (pmPBase, pmTol2ase, or pSBase, 
respectively) at 9:1 ratio (w/w) to generate the cell populations labeled (A) PB (+), (B) Tol2 (+), and (C) SB 
(+), respectively. Transfections were also conducted with each donor vector and filler DNA at 9:1 ratio (w/w) 
to generate cell populations (A) PB (-), (B) Tol2 (-), and (C) SB (-), respectively. For each transposon system, 
transfections were performed in CHO-DG44, CHO-K1, and CHO-S. The cells were cultivated in the absence 
of selective pressure with passage every 3-4 days. The percentage of EGFP-positive cells in each culture was 
determined by flow cytometry at the times indicated. The results for each condition are represented as average 





5.2.2. Volumetric productivities of transposon-mediated cell pools derived from 
 different CHO strains  
The three CHO strains were co-transfected with the donor vectors pMP-PB-TNFR:Fc, 
pSBP-Tol2-TNFR:Fc, or pSBP-SB-TNFR:Fc along with their respective helper vectors 
pmPBase, pmTol2ase, or pSBase, respectively. Cells were also co-transfected with each 
donor vector and filler DNA at a ratio of 9:1 (w/w). For each transfection, a cell pool was 
generated by selection in puromycin as described in Chapter 2. Briefly, the cells were 
cultivated in the presence of 10 µg/mL puromycin for 10 days starting at day 2 post-
transfection. The TNFR:Fc productivity of the pools was analyzed from a 4-day batch 
culture grown in the absence of selection. For all three CHO strains, a 3-4 fold improvement 
in the volumetric TNFR:Fc productivity of the cell pools was observed in the presence of 
the three transposases as compared to the productivities of the cell pools generated by 
conventional plasmid transfection (Fig. 5.2). The highest productivities were achieved in 
CHO-K-derived cell pools when using the PB and Tol2 systems and in CHO-DG44-derived 
cell pools when using the SB system (Fig. 5.2 A-C). The lowest productivity for each 









Figure 5.2. Volumetric productivities of cell pools generated with different transposons and CHO 
strains. Different CHO strains as indicated were transfected in duplicate with a donor vector (pMP-PB-IRES-
EGFP, pSBP-Tol2-IRES-EGFP, or pSBP-SB-IRES-EGFP) and a helper vector pmPBase, pmTol2ase, or 
pSBase, respectively, at a ratio of 9:1 (w/w) to generate cell pools labeled (A) +PBase, (B) +Tol2ase, or (C) 
+SBase, respectively. Cells were also co-transfected with each donor vector alone and filler DNA at a 9:1 
ratio (w/w) to generate cell pools labeled (A) -PBase, (B) -Tol2ase, or (C) -SBase. Cell pools were generated 
by selecting transfected cells with puromycin (10 µg/mL) for 10 days. The volumetric productivities were 
measured by ELISA at the end of 4-day batch cultures. Each ELISA measurement was performed in duplicate. 
Thus, the error bars represent the standard deviation from 4 different measurements as each culture was 





5.2.3. Analysis of stability of volumetric protein production in cell pools 
Cell pools generated with different transposons as described in Section 5.2.2 were 
cultivated in the absence of selection for up to 2 months with passage every 3-4 days. The 
productivity of each cell pool was determined periodically at the end of 4-day batch cultures 
starting from a culture seeded at 0.3 x 106 cells/mL. The cell pools generated with CHO-
DG44 lost 50 % of their productivity within 30 days and then the productivity remained 
constant (Fig. 5.3 A-C). In contrast, the volumetric productivity of cell pools generated 
with either CHO-K1 or CHO-S cells declined with time to levels observed in the cell pools 









Figure 5.3. Analysis of the volumetric productivity of cell pools generated with PB, Tol2 or SB. Cell 
pools were generated with the PB (A), Tol2 (B), or SB (C) transposon systems in the presence (+) or absence 
(-) of the helper vector as indicated in Fig. 5.2. After selection in 10 µg/mL puromycin for 10 days, the cell 
pools were grown in the absence of selection for 2 months with passage every 3-4 days. The volumetric 







5.2.4. Analysis of the integrated transgene copy number in cell pools.  
The average number of integrated TNFR:Fc genes was determined by RT-qPCR at the 
beginning and end of the cultures described in Fig. 5.3. For all three transposon systems, 
the average integrated transgene copy number for the cell pools cultivated in the absence 
of selection for 1 week was similar for those cell pools originating from the CHO-DG44 
and CHO-K1 strains (Fig. 5.4 A-C). For the PB and SB transposon systems, however, the 
average integrated transgene copy number was ~50 % lower for cell pools originating from 
the CHO-S strain as compared to those cell pools derived from the CHO-DG44 and CHO-
K1 strains (Fig. 5.4A, C). The CHO-S-derived cell pools generated with the PB and SB 
transposon systems also had low volumetric productivities (Fig. 5.2). We observed a loss 
of ~50% and ~30% of the transgene copies in the cell pools derived from the CHO-K1 and 
CHO-S strains, respectively, following transfected with the PB transposon system (Fig. 
5.4A). These results may explain the decline of the volumetric protein yield over time in 
these two cell pools (Fig. 5.3). For all other combinations of transposon system and CHO 
strain, there was no loss in the integrated transgene copy number by cultivating the cells in 









Figure 5.4. Determination of integrated TNFR:Fc gene copy number in cell pools generated with 
different transposons. Cell pools were generated with the PB (A), Tol2 (B), and SB (C) transposon systems 
as described in Fig. 5.2. The average number of integrated copies of the TNFR:Fc gene per cell in each pool 








The applicability of the PB, Tol2, and SB transposon systems for the efficient generation 
of cell pools was extended to two other CHO cell strains, CHO-K1 and CHO-S. The fold 
improvement in TNFR:Fc productivity of the transposon-mediated cell pools, compared to 
cell pools generated by conventional transfection, was very similar in all three cell lines. 
The highest volumetric protein yields were obtained using the PB or Tol2 transposon 
system in CHO-K1 cells. Of the three strains, the host with the lowest volumetric 
productivities was CHO-S. However, the cell pools generated with CHO-K1 and CHO-S 
cells were very unstable and the protein productivity declined to the level of pools generated 
by conventional transfection in just 4-5 weeks of cultivation in the absence of selection.  
Although there was a decline in protein productivity of the cell pools with time in culture 
for most combinations of transposon system and cell host, this was not due to a loss of 
copies of the integrated transgene. In cell pools with no loss in gene copy numbers, the 
decline in protein productivity was assumed to be due to transgene silencing. For cell pools 
in which there was a decline in the average number of integrated transgenes with time, the 
loss in protein productivity could be attributed to the physical loss of transgene copies or 
overgrowth of the culture with cells having lower protein production levels (Chusainow et 
al. 2009; Yang et al. 2010). Cell pools can be maintained in the presence of selective 
pressure until used for the protein production phase (Ye et al. 2010). This may help 
maintain the protein productivity over time.  
All the transposon-mediated cell pools had 3-4 fold higher volumetric protein productivity 
levels compared to cell pools generated by conventional plasmid transfection. The uniform 
improvement in protein yield using transposon systems was very promising, considering 
that the protocols (selection parameters, donor: helper DNA amounts, medium etc.) were 
not optimized for CHO-K1 and CHO-S. Eventually, CHO-DG44 were the most suitable 
host cells for generating the cell pools with the three transposons, as the cell pools had good 
volumetric productivities and the production levels were more stable over time compared 
to those generated with CHO-K1 and CHO-S cells. We speculate that the differences in the 
final volumetric productivities and stability of protein production of the transposon-





for cell pool generation. Cell strain-specific optimization studies will be required to further 
improve the systems in terms of the stability of protein production over time. However, 
these optimization studies for the CHO-K1 and CHO-S cell strains were not in the scope 
of this thesis. The LBTC has successfully used the PB transposon system for cell pool 
generation in HEK293 and S2 cells (not published). 
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Cell Pools Expressing Multiple Transgenes 












In biomedical research and drug development there is often a need for multiple genes to be 
co-expressed in the same cell. The applications extend from expression of multi-subunit 
proteins to co-expression of a chaperone protein or other partner proteins with the protein 
of interest (Alattia et al. 2013; Chung et al. 2004; Hwang et al. 2003; Kahlig et al. 2009; 
Mastrangelo et al. 2000; Mohan et al. 2008). Conventional approaches are based on the 
transfection of host cells with multiple expression cassettes, either carried in a single 
plasmid or in multiple plasmids. This often results in inefficient integration and expression 
of one or more of the transgenes, especially when relying on DNA recombination for 
integration (Mansouri and Berger 2014). Another method is by sequential transfection of 
the host cell with each transgene to generate cell lines iteratively, which is time-consuming 
and laborious (Cacquevel et al. 2008; McPhaul and Berg 1986; Paul et al. 1985). Several 
other strategies are now commonly used for co-expression of multiple proteins including 
IRES-containing polycistronic genes, polyproteins that contain one or more self-cleaving 
protease sites, and viruses that contain multiple recombinant genes (Berger et al. 2013; 
Donnelly et al. 2001; Ghattas et al. 1991; Ho et al. 2013). Recently, the PB transposon 
system has been successfully used for the generation of cell lines co-expressing multiple 
proteins in CHO and HEK293 host cells (Alattia et al. 2013; Kahlig et al. 2009; Li et al. 
2013). In Alattia et al. (2013), the co-transposition of two PB transposons, each carrying 
the genes of two of the four γ – secretase subunits and a selection gene, allowed CHO cell 
lines expressing fully functional γ – secretase to be generated. Using the PB transposon 
system, a considerable improvement was shown in active γ – secretase production over 
other available systems. Li et al. (2013) used the PB transposon system to co-transfect up 
to 2 artificial transposon to generate doxicyclin-inducible HEK-293 cell pools and cell lines 
expressing monoclonal antibodies. Kahlig et al. (2009) co-transfected HEK-293 cells with 
up to 4 artificial PB transposons to generate cell lines expressing a multisubunit neuronal 
voltage-gated sodium channel (SCN1A). 
Despite these successes, a thorough study on the optimization of the conditions for the 
generation of CHO cell pools expressing multiple transgenes has not been performed. Here, 





multiple proteins were generated by simultaneous delivery of up to four transgenes into 
CHO-DG44 cells. Enhanced green fluorescent protein (EGFP), secreted alkaline 
phosphatase (SEAP), and the light (LC) and heavy chains (HC) of an IgG1 antibody were 
used as the four model proteins. Studies were conducted to create cell pools expressing 
different combinations of the four transgenes with one or multiple selection genes. The 
percentage of cells simultaneously co-expressing all the transgenes in a pool was also 






6.2.  Results 
6.2.1. Protein productivity of cell pools co-expressing multiple proteins  
We generated cell pools expressing up to 4 transgenes with and without the PB transposon 
system using the genes for EGFP, SEAP, and the LC and HC of an IgG1 antibody. Cell 
pools expressing 1, 2, 3 or 4 transgenes were generated as indicated in Table 6.1. The 
amount of each donor plasmid was kept constant at 22.5% of the total transfected DNA, 
irrespective of the number of different plasmids transfected. The helper vector pmPBase or 
filler DNA was included to 10% of the total transfected DNA or replaced with filler DNA 
(Table 6.1). All donor plasmids contained the pac gene as the selection marker.  



















1 22.5% –– –– –– –– 77.5% 
2 22.5% 22.5% –– –– –– 55% 
3 22.5% –– 22.5% 22.5% –– 32.5% 
4 22.5% 22.5% 22.5% 22.5% –– 10% 
PB 
1 22.5% –– –– –– 10% 67.5% 
2 22.5% 22.5% –– –– 10% 45% 
3 22.5% –– 22.5% 22.5% 10% 22.5% 
4 22.5% 22.5% 22.5% 22.5% 10% –– 
 
The cell pools were generated by selecting with two different puromycin concentrations 
(10 µg/mL and 50 µg/mL) for a duration of 10 days, starting from day 2 post-transfection. 
The cell pools transfected with PB transposon, when selected with 10 µg/mL or 50 µg/mL 
puromycin, resulted in pools PB-10p and PB-50p, respectively. The cell pools generated 
by conventional plasmid transfection resulted in pool TX-10p (selected with 10 µg/mL 
puromycin) as the cells did not survive 50 µg/mL puromycin. Cell pools expressing one 
(EGFP), two (EGFP and SEAP), three (EGFP and IgG), or four (EGFP, SEAP, and IgG) 
transgenes were recovered. The EGFP-specific fluorescence, SEAP activity, and IgG 
concentration were measured at the end of 4-day batch cultures performed in the absence 
of selection. 
Use of the PB transposon system for the generation of cell pools resulted in higher 





6.1B), SEAP activity (Fig. 6.1C), and IgG concentrations (Fig. 6.1D) as compared to the 
cell pools from conventional plasmid transfection. For the use of the PB transposon system 
in the presence of a high stringency of selection (PB-50p), protein production was generally 
higher than in the cell pools resulting from selection at a lower level of stringency (PB-
10p) (Fig. 6.1 B-D). However, the expression of individual proteins decreased as the total 









Figure 6.1. Protein production levels for cell pools expressing multiple transgenes. Cell pools expressing 
1, 2, 3 or 4 transgenes, as indicated, were analyzed. The cell pools generated in the absence of the PB helper 
vector were selected with 10 µg/mL puromycin (TX-10p) and the cell pools generated with the PB system 
were selected with either 10 µg/mL (PB-10p) or 50 µg/mL (PB-50p) puromycin. Protein production was 
measured at the end of 4-day batch cultures without puromycin. EGFP-specific fluorescence was measured 
by flow cytometry to determine (A) the % EGFP-positive cells and (B) the relative fluorescence units (RFU). 
(C) SEAP activity was measured by an enzymatic assay, and (D) the IgG concentration in the medium was 
measured by ELISA. The error bars represent the standard deviation from 4 different measurements as each 





6.2.2. Analysis of the average integrated transgene copy number in cell pools co-
 expressing multiple proteins 
The number of integrated copies of each transgene in each cell pool was determined by RT-
qPCR. In cell pools from all three conditions (TX-10p, PB-10p, PB-50p), the number of 
copies of each transgene decreased with the number of transgenes co-transfected (Fig. 6.2 
A-D). This decrease in transgene copy number correlated to a decrease in the expression 
level of each protein. The average gene copy number for each gene in the four PB-10p cell 
pools was lower than that of the corresponding gene in the TX-10p cell pools even though 
the protein expression levels were higher in the former (Fig. 6.1 A-D). Also, the PB-50p 
cell pools had a slightly higher number of copies of each gene per cell as compared to the 
PB-10p cell pools (Fig. 6.2A-D). This difference correlated with higher protein production 
levels in the PB-50p cell pools (Fig. 6.1 A-D). Interestingly, we observed that the total 
number of integrated transgene copies for each PB-50p cell pool was similar (Fig. 6.3). 
Additionally, the number of integrated copies of each transfected transgene for each PB-
50p cell pool was similar, with the exception of the IgG-HC gene. A similar trend was also 









Figure 6.2. Analysis of transgene integration in cell pools. Cell pools expressing 1, 2, 3 or 4 transgenes 
were generated in the presence (PB-10p, PB-50p) or absence (TX-10p) of PBase. Cell pools expressed the 
protein(s) as indicated in each bar graph. The cell pools generated in the absence of the PB helper vector were 
selected with 10 µg/mL puromycin (TX-10p), and the cell pools generated with the PB system were selected 
with either 10 µg/mL (PB-10p) or 50 µg/mL (PB-50p) puromycin. The average number of integrated (A) 
EGFP, (B) SEAP, (C) IgG-LC, and (D) IgG-HC genes was estimated by RT-qPCR. The error bars represent 
the standard deviation from 4 different measurements as each culture and each analytical measurement was 







Figure 6.3. Distribution of the integrated gene copies in the PB-50p cell pools. Cell pools expressing 1, 
2, 3 or 4 transgenes, as indicated in Table 6.1, were generated in the presence of PBase. The PB-Multiselection 
cell pools were generated by selecting the cells with 50 µg/mL puromycin (PB-50p). Cell pools were 
expressing the protein(s) as indicated. The integrated number of each gene was estimated by RT-qPCR. The 
copy number of each individual transgene is represented in a stack so as to present the total sum integrated 
gene copy number for each pool. 
6.2.3. Protein expression stability of cell pools co-expressing multiple proteins  
The stability of protein production of the cell pools described in section 6.2.2 was 
determined over a 50-day cultivation period in the absence of selection. The production of 
each protein was determined periodically in 4-day batch cultures. For the four TX-10p cell 
pools, the % of EGFP-positive cells decreased by 20 – 25 % from the start to the finish of 
the cultivation period (Fig. 6.4A). But the EGFP expression level, represented by the 
relative fluorescence units (RFU), remained relatively constant for all four cell pools (Fig. 
6.4B). On the other hand, the yields of the secreted proteins SEAP and IgG decreased to 






   
   
Figure 6.4. Volumetric protein production over time from cell pools resulting from conventional 
transfection. Cell pools expressing 1, 2, 3 or 4 transgenes were generated in the absence of PBase by selecting 
with a puromycin concentration of 10 µg/mL (TX-10p). Cell pools expressed the protein(s) as indicated. The 
stability of protein expression over time was determined by measuring (A, B) EGFP-specific fluorescence, 
(C) SEAP activity, and (D) IgG concentration. The cell pools were maintained in the absence of selection for 
50 days and regularly analyzing at the end of 4-day batch cultures at the times indicated. The data here is 
represented relative to the expression level at the first point of measurement for each cell pool. 
The % of EGFP-positive cells in PB-mediated cell pools was more stable than that observed 
for the TX-10p cell pools (Fig. 6.5A; Fig. 6.6A). In the PB-10p and PB-50p cell pools at 
least 90 % of the cells remained EGFP-positive for the duration of the cultivation period in 
contrast to 70 – 75 % EGFP-positive cells for the TX-10p cell pools (Fig. 6.5A; Fig. 6.6A). 
As seen for the TX-10p cell pools, the expression levels of EGFP (reported as RFU) 
appeared to be constant over time for the PB-mediated cell pools (Fig. 6.5B, 6.6B). For PB-





observed over time, as for the TX-10p cell pools (Fig. 6.5C, D). Similar declines in SEAP 
activity and IgG concentration were observed for the PB-50p cell pools (Fig. 6.6C, D).  
   
   
Figure 6.5. Volumetric protein production over time from PB-10p cell pools. Cell pools expressing 1, 2, 
3 or 4 transgenes were generated in the presence of PBase by selecting with a puromycin concentration of 10 
µg/mL (PB-10p). Cell pools expressed the protein(s) as indicated. The stability of protein expression over 
time was determined by measuring (A, B) EGFP-specific fluorescence, (C) SEAP activity, and (D) IgG 
concentration. The cell pools were maintained in the absence of selection for 50 days and regularly analyzing 
at the end of 4-day batch cultures at the times indicated. The data is represented relative to the expression 







Figure 6.6. Volumetric protein production over time from PB-50p cell pools. Cell pools expressing 1, 2, 
3 or 4 transgenes were generated in the presence of PBase by selecting with a puromycin concentration of 50 
µg/mL (PB-10p). Cell pools expressed the protein(s) as indicated. The stability of protein expression over 
time was determined by measuring (A, B) EGFP-specific fluorescence, (C) SEAP activity, and (D) IgG 
concentration. The cell pools were maintained in the absence of selection for 50 days and regularly analyzing 
at the end of 4-day batch cultures at the times indicated. The data is represented relative to the expression 
level at the first point of measurement for each cell pool.  
6.2.4. Generation of cell pools co-expressing individually-selected proteins 
All of the cell pools described earlier in this chapter were generated by using a single 
selection gene. However, we observed that in PB-mediated cell pools, the total number of 
transgene integrations was nearly distributed equally among the different transgenes. With 
the aim of increasing the number of integrations of each transgene and improving the 





donor vectors, each having a different selection gene (Table 6.2). The donor plasmids are 
described in Table 2.1. The selection markers were chosen based on previous results 
described in Chapter 3 (see Fig. 3.3). PB-mediated cell pools co-expressing 1, 2, 3, or 4 
transgenes were generated as indicated in Table 6.2. The cells were then co-selected with 
the appropriate combination of 10 µg/mL puromycin, 10 µg/mL blasticidin, 200 µg/mL 
hygromycin B, and 50 µg/mL zeocin to generate PB-Multiselection cell pools for each of 
the four transfections. The cells were placed under selection pressure until the cell viability 
increased to >90 %. The EGFP-specific fluorescence, SEAP activity, and IgG 
concentration were measured at the end of 4-day batch cultures in the absence of selective 
pressure. The productivities of the cell pools are shown in comparison with PB-mediated 
cell pools generated by selection with puromycin (50 µg/mL) as described in section 6.2.1 
(PB-50p). 
















1 22.5% –– –– –– 10% 67.5% 
2 22.5% 22.5% –– –– 10% 45% 
3 22.5% –– 22.5% 22.5% 10% 22.5% 
4 22.5% 22.5% 22.5% 22.5% 10% –– 
aContains selection marker bsr (blasticidin S-resistance gene); bContains selection marker hph (hygromycin 
B phosphotransferase gene); bContains selection marker pac (puromycin N-acetyl-transferase); dContains 
selection marker Sh ble (ble gene from Streptoalloteichus hindustanus).  
For PB-Multiselection cell pools, EGFP expression (Fig. 6.7A, B) and SEAP activity levels 
(Fig. 6.7C) were slightly higher than for corresponding PB-50p cell pools. In contrast, IgG 
production was lower in the PB-Multiselection cell pools as compared to the PB-50p cell 







Figure 6.7. Protein expression levels of PB-Multiselection cells pools. Cell pools expressing 1, 2, 3 or 4 
transgenes, as indicated in Table 6.2, were generated in the presence of PBase. Cell pools expressed the 
protein(s) as indicated. The PB-50p cell pools were generated by selecting with a puromycin concentration 
of 50 µg/mL as described in Section 6.2.1. The PB-Multiselection cell pools were generated by selecting with 
the appropriate combination of antibiotics as indicated in Table 6.2. (A, B) EGFP-specific fluorescence was 
measured by flow cytometry, (C) the SEAP activity was measured by an enzymatic assay, and (D) the IgG 
concentration was measured by ELISA at the end of 4-day batch cultures in the absence of selection. The 
error bars represent the standard deviation from 4 different measurements as each culture and each analytical 
measurement was performed in duplicate.  
The number of integrated transgene copies in the PB-50p and PB-Multiselection cell pools 
was determined by RT-qPCR. In contrast to the minor differences in expression levels of 
the different proteins in the two sets of cell pools, there were significant differences in the 





a decrease in the integrated copy number of each transgene with an increase in the number 
of transfected genes. For the PB-Multiselection cell pools, however, the integrated copy 
number of each transgene was similar irrespective of the number of transgenes transfected 
(Fig. 6.8 A-D).   
  
  
Figure 6.8. Average integrated gene copy number in PB-Multiselection and PB-50p cell pools. Cell pools 
expressing 1, 2, 3 or 4 transgenes were generated as described in Figure 6.7. The integrated copy number of 
the (A) EGFP, (B) SEAP, (C) IgG-LC, and (D) IgG-HC genes was estimated by RT-qPCR. The error bars 
represent the standard deviation from 4 different measurements as each culture and each analytical 
measurement was performed in duplicate. 
In pools PB-10p and PB-50p, we observed a total of 10-12 integrated transgenes per cell 





copies) (Fig. 6.3). For the PB-Multiselection cell pools, there were about 6-8 integrated 
copies of each gene with the exception of the IgG-HC gene (1.5 copies) (Fig. 6.9). Thus, 
the total number of integrated transgenes per cell increased by selecting each individual 
GOI with the total number of integrated genes reaching 25 for the cell pool expressing all 
4 transgenes (Fig. 6.9). However, this increase in the number of integrated transgenes did 
not translate into increased protein productivity (Fig. 6.7). 
 
Figure 6.9. Distribution of the integrated gene copies in the PB-Multiselection cell pools. Cell pools 
expressing 1, 2, 3 or 4 transgenes, as indicated in Table 6.2, were generated in the presence of PBase. The 
PB-Multiselection cell pools were generated as described in Figure 6.7. The integrated copy number of each 
gene was estimated by RT-qPCR. The copy number of each individual transgene is represented in a stack so 
as to present the total number of transgene copies for each pool. 
To determine the stability of protein production by the PB-Multiselection cell pools, each 
one was cultivated in the absence of selection for 4 weeks. The level of each protein was 
determined periodically from 4-day batch cultures. For the four cell pools, the percentage 
of EGFP-positive cells remained constant with time (Fig. 6.10A). In contrast, for three of 
the four cell pools, the level of EGFP-specific fluorescence per cell declined with time (Fig. 
6.10B). The levels of SEAP activity and IgG concentration tended to decrease with time as 







Figure 6.10. Protein production with time in culture for PB-Multiselection cell pools. Cell pools 
expressing 1, 2, 3 or 4 transgenes, as indicated in Table 6.2, were generated in the presence of PBase by 
selecting the cells with the appropriate combination of antibiotics as described in Figure 6.7. Cell pools 
expressed the protein(s) as indicated. The levels of (A, B) EGFP-specific fluorescence, (C) SEAP activity, 
and (D) IgG concentration were assessed by maintaining the cells in absence of selection for 30 days, and the 
protein levels were analyzed at the times indicated at the end of 4-day batch cultures. The data is represented 
relative to the expression level at the first point of measurement for each cell pool. 
6.2.5. Analyses of cell pools co-expressing multiple fluorescent proteins 
PB-mediated cell pools expressing 3 proteins (PB-10p, PB-50p and PB-Multiselection) had 
up to 35-fold higher productivity levels compared to those generated by conventional 
plasmid transfection (TX-10p) (see Fig. 6.1). We hypothesized that these cell pools had a 
higher percentage of cells expressing all three proteins than the pools generated by 





EGFP (green) and mCherry (red) fluorescent proteins were generated with and without the 
PB transposon system as described in Table 6.3. All donor plasmids contained the pac gene 
(resistance against puromycin) as the selection marker. The cells pools were generated by 
selecting with puromycin (10 µg/mL) for 10 days starting from day 2 post-transfection. 
Table 6.3. DNA amounts for cell pool generation with 3 different fluorescent proteins. 
Cell pool 






pmPBase Filler DNA 
TX-fluorescent 33.3% 33.3% 33.3% –– 10% 
PB-fluorescent 33.3% 33.3% 33.3% 10% - 
The percentage of cells in each cell pool (TX-fluorescent and PB-florescent) that expressed 
one or more fluorescent proteins was determined using a flow cytometer. In the TX-
fluorescent cell pool, 30% of the cells failed to express any of the fluorescent proteins, 
while 7% of the cells expressed all three proteins (Fig. 6.11). For the PB-fluorescent cell 
pool, in contrast, only 4% of the cells failed to express any of the three fluorescent proteins, 
while 23% of the cells expressed all three proteins (Fig. 6.11). These results, in combination 
with the protein production improvements seen for the PB-10p, PB-50p and PB-
Multiselection cell pools compared to the TX-10p cell pools, indicated that the probability 
of finding cells co-expressing multiple transgenes would be higher from a transposon-
mediated cell pool than from a cell pool generated by conventional transfection. This would 
in turn increase the efficiency of generating multigene-expressing clonal cell lines from the 








Figure 6.11. Fluorescence distribution profile in PB-fluorescent and TX-fluorescent cell pools. Cell pool 
expressing the fluorescent proteins Cerulean, EGFP and mCherry were generated by transfecting with pSB-
PPB-Cer, pMP-PB-EGFP and pSB-PPB-mCh in a 1:1:1 ratio in the absence (TX-fluorescent) and presence 
(PB-fluorescent) of PBase. The X-axis indicates the number of fluorescent proteins expressed by a cell. This 
distribution was generated from 50,000 cells. The error bars represent the standard deviation between 
experimental duplicates.  
6.2.6. Generation of clonal cell lines co-expressing multiple proteins.  
We recovered 48 clonal cell lines from the PB-50p cell pool expressing EGFP, SEAP, and 
IgG as described in Section 6.2.1. The EGFP-specific fluorescence, SEAP activity, and IgG 
concentration for each cell line was measured at the end of 4-day batch cultures in 24-well 
plates. About 10 % of the cell lines failed to express one of the proteins, 30 – 35 % 
expressed one or two proteins, and 25 % expressed all three proteins, albeit at different 
levels (Fig. 6.12). This correlated with the fluorescence distribution profile of the PB-







Figure 6.12. Distribution profile of cell lines. Clonal cell lines (n=48) were generated from the PB-50p cell 
pool expressing EGFP, SEAP, and IgG. The X-axis indicates the number of proteins expressed by the cell 
lines. The Y-axis indicates the % of cell lines expressing said number of proteins. EGFP-specific fluorescence 
was measured by FACS, SEAP activity was measured by an enzymatic assay, and the IgG concentration was 










The PB transposon system has been successfully used for the generation of cell lines co-
expressing multiple proteins in CHO and HEK293 host cells (Alattia et al. 2013; Kahlig et 
al. 2009; Li et al. 2013). In this chapter, we studied the generation of cell pools and cell 
lines expressing up to 4 transgenes with the PB transposon system and by conventional 
transfection using EGFP, SEAP, and the light and heavy chains of an IgG1 antibody as the 
four model proteins.  
The productivities of the PB-10p and PB-50p cell pools were higher than those of the 
conventionally generated TX-10p cell pools. The expression levels of SEAP and IgG were 
up to 10 fold and 35 fold higher, respectively, in PB-mediated cell pools compared to the 
cell pools generated by conventional transfection. Increasing the selection stringency for 
the generation of the PB-50p cell pools resulted in only a slight improvement in protein 
production except for IgG, as compared to the PB-10p cell pools. By conventional 
transfection, we were able to generate cell pools co-expressing all four proteins, albeit with 
low expression levels. The expression level of each protein for the TX-10, PB-10p and PB-
50p cell pools was found to decrease as the number of transfected transgenes increased. For 
the PB-10p and PB-50p cell pools, the number of integrated copies of each transgene also 
decreased as the number of transfected transgenes increased.  
For PB-10p and PB-50p cell pools, the total number of integrated transgenes was similar 
(about 10-12 copies/cell) irrespective of the number of different donor vectors transfected. 
In these cell pools, each gene except the IgG-HC gene, was equally represented among the 
integrated transgenes. This indicated that with the PB transposon system there was little 
bias in transgene integration. In cell pools in which IgG was produced, there was usually 
only 1-2 copies/cell of the IgG-HC gene, in spite of the vector backbone being the same as 
that of the other donor plasmids. The size of the artificial transposon could not have been a 
factor since the SEAP and IgG-HC genes have about the same number of base pairs. It has 
also been shown that cell lines expressing high levels of anti-rhesusD IgG had fewer 
integrated copies of the IgG-HC gene compared to that of the IgG-LC gene (Chusainow et 
al. 2009; Ho et al. 2013; Li et al. 2007; O'Callaghan et al. 2010). It may be that similar 





Although there was an increase in transgene expression for cell pools derived with the PB 
transposon system than those resulting from conventional transfection, the PB-10p and PB-
50p cell pools had similar losses in protein production over time as did the TX-10p cell 
pools. Our studies of the stability of protein production demonstrated a difference in the 
behavior of secreted proteins versus intracellular proteins. The EGFP production level 
tended to be constant over time whereas the production of SEAP and IgG decreased with 
time. Further investigation is required to identify if the reason for stable expression of 
EGFP was protein-specific. 
We used genes conferring resistance to different selection markers on each transgene with 
the aim to increase the number of integrated transgenes and consequently improve the level 
and stability of protein productivity. The PB-Multiselection cell pools were generated by 
simultaneously selecting with up to four antibiotics at their optimal concentrations. The 
resulting cell pools had only slightly higher protein production levels compared to the PB-
50p cell pools even though the integrated copy number of each transgene was higher in PB-
Multiselection cell pools than in the comparable PB-50p cell pools. For the PB-
Multiselection cell pools, 6-8 copies of each transgene, except the IgG-HC gene (1.5 
copies/cell), were present. We observed the same phenomenon in the PB-10p and PB-50p 
cell pools. Thus, the total sum of transgene integration events increased with the increase 
in the number of different transgenes transfected. The expression levels of the individual 
proteins in the PB-Multiselection cell pools decreased over a cultivation period of 30 days 
in the absence of selection. This trend was also observed for the PB-10p and PB-50p cell 
pools. Further studies are required to understand the principal cause of the decline in protein 
productivity over time.  
The fact that we saw an increase in the average integrated transgene copy number in the 
PB-Multiselection cell pools compared to the PB-50p cell pools, without a proportional 
increase in in protein yield, lead us to speculate that there may be other limitations to protein 
yield besides transgene copy number. There could be transcriptional, translational, or post-
translational limitations to protein production. It is also possible that the selection regime 
necessary for the generation of the PB-Multiselection cell pools increased the frequency of 





integrated by DNA recombination would be expected to have had a minimal contribution 
to transgene expression levels.  
We also generated cell pools expressing three different fluorescent proteins. With these cell 
pools we were able to analyze the percentage of cells expressing 1, 2 or 3 proteins. The 
results showed that the percentage of cells co-expressing all 3 fluorescent proteins 
increased by 3 fold in the PB-fluorescent cell pool as compared to the TX-fluorescent cell 
pool generated by conventional transfection. This indicates that the use of PB-mediated cell 
pools may significantly reduce the screen size required for generating cell lines co-
expressing multiple proteins. This was supported by our study where we were able to obtain 
12 out of 48 clonal cell lines from PB-50p cell pools co-expressing the three proteins EGFP, 
SEAP and IgG.  
In our experience, use PB transposon system improved both the volumetric productivities 
and the percentage of cells co-expressing multiple proteins in the cell pool as compared to 
those generated by conventional transfection, making it a viable strategy for multi-protein 
production both from cell pools and cell lines. 






Conclusions and Perspectives 
  










The overall goal of this thesis was to evaluate the efficiency of generation of cell pools and 
cell lines in CHO cells by using transposon systems for catalyzing transgene integration. 
Three of the commonly used transposon systems, piggyBac (PB), Tol2, and Sleeping 
Beauty (SB), were studied.  
Through optimizations of several parameters we showed that PB-mediated cell pools could 
be generated in CHO-DG44 cells with a selection duration of 5-10 days in the presence of 
puromycin, resulting in cell pools with productivities 3-4 times higher than those generated 
by conventional plasmid transfection. We were able to generate cell pools with similar 
volumetric productivities by addition of the selection agent anytime between 1-3 days post-
transfection. Similar volumetric productivities were obtained from cell pools by selecting 
with different antibiotic resistance genes. In 14-day batch cultures, TNFR:Fc productivities 
of 350-550 mg/L were reproducibly obtained from five independent PB-mediated cell 
pools. Thereby, we established a reproducible protocol for the generation of transposon-
mediated cell pools.  
The PB, Tol2 and SB transposon systems behaved similarly in terms of cell pool and cell 
line generation in CHO-DG44 cells. All three transposon systems generated cell pools with 
similar volumetric TNFR:Fc productivities (80 – 100 mg/L) and integrated transgene 
copies (10 – 12 copies/cell). The volumetric productivities of the transposon-mediated cell 
pools were ~9 fold higher than those generated by conventional transfection using donor 
vectors without inverted transposon repeats. Some of the integration events in the cell pools 
occurred via DNA recombination rather than transposition. About 75 % of the integration 
events in PB- and SB- mediated cell pools occurred via transposition, whereas only 40 % 
of integrations were via transposition in Tol2-mediated cell pools. The higher levels of 
protein production observed in the transposon-mediated cell pools correlated with higher 
levels of transgene mRNA (Table 7.1). As expected, the average volumetric TNFR:Fc 
productivity of transposon-derived cell lines was higher than that of cell lines generated by 
conventional transfection (Table 7.1). From 14-day fed-batch cultures, protein levels up to 
900 mg/L and 1.5 g/L were obtained from transposon-mediated cell pools and cell lines, 
respectively. The productivity of the cell pools, however, decreased to 50 % the initial value 




when cultivated in the absence of selection for 3 months. However, the volumetric protein 
yield from transposon-mediated cell lines remained constant for up to 4 months in the 
absence of selection.  
The method of generating transposon-mediated cell pools was also applied to two other 
CHO cell strains, CHO-K1 and CHO-S. We showed that the three transposon systems could 
be used for cell pool generation with CHO-K1 and CHO-S with similar volumetric 
productivities as observed with CHO-DG44 cells (70 – 100 mg/L). However, the 
expression levels of the transposon-mediated cell pools in CHO-K1 and CHO-S were 
unstable and demonstrated a decrease in productivity to the level of cell pools generated by 
conventional transfection. Thus, CHO-DG44 was the best host cell choice for the 
generation of cell pools using transposon systems for gene delivery. 
We also utilized the PB transposon system for generating cell pools co-expressing up to 4 
different transgenes for EGFP, SEAP, and the LC and HC of an IgG1 monoclonal antibody, 
by simultaneous gene transfer. We showed that PB-mediated cell pools had increased 
volumetric productivity of each of the proteins compared to those generated by 
conventional co-transfection. We compared two strategies for generation of cell pools, 
using either the same or different selection markers for each transgene. Although co-
selecting the cells with multiple antibiotics showed differences in the viability profiles and 
the integrated gene copy numbers, it did not have a significant effect on protein productivity 
and stability compared to the cell pools selected with single selection marker. By analyzing 
the composition of the cell pools and generation of cell lines we demonstrated that the use 
of the PB transposon system increased the percentage of cell population that co-expressed 
all four proteins as compared to the results with cell pools generated by conventional 
transfection.  
Based on our experience with the use of transposon systems for recombinant protein 
production, we deduced that this method provides a good balance between gene delivery 
in the presence of DNA regulatory elements and targeted gene integration in terms of the 
ease of setup and the output generated. The vector engineering required for the construction 
of artificial transposons is very simple, making it easily applicable (Table 7.1). Transposon 




systems are a semi-targeted system which do not require host cell engineering or pre-
characterization of integration hotspots in the host cell genome, thereby eliminating the 
requirement of cell line- or protein-specific optimization for each protein production 
project. In conclusion, the transfection of CHO-DG44 cells with the PB, Tol2 or SB 
transposon system is a simple, efficient, and reproducible approach to the generation of cell 
pools and cell lines for the rapid production of recombinant proteins. 
Table 7.1. Summary of advantages of transposon system for recombinant protein 
production 
Method for gene integration/Cell line generation  
Transposon systems Advantages 
Simple construction and delivery 
Semi-targeted integration 
Better utilization of integrated transgene copies for gene 
expression 
Reduction in screen size to identify suitable clonal cell lines 
Easily applicable to different GOIs tested in this study  








7.2. Future Perspectives 
Although we have studied the use of transposon systems for cell pool and cell line 
generation in detail, there are various aspects that still need to be better defined.  
7.2.1. Product quality analysis for cell pools 
Cell pools are typically not the method of choice for therapeutic protein production due to 
the heterogeneity of the cell population. However, there is currently some interest in using 
cell pools as a method for generating material for preclinical stages of therapeutic protein 
development. Here, we have improved the volumetric productivities of cell pools using 
transposon systems. To eventually be used for early drug development stages, it is 
important that the products from cell pools are similar to those produced from cell lines. 
Hence there is a need to compare product attributes, such as the glycan profile of 
glycosylated proteins, protein degradation, protein aggregation, and posttranslational 
modifications other than glycosylation of recombinant proteins produced from cell pools 
and cell lines. 
Additionally, the awareness of intraclonal genetic variation of cell lines in culture, resulting 
in a heterogeneous population not unlike a cell pool, increases the likelihood of use of cell 
pools for commercial protein production (Pilbrough et al. 2009; Wurm 2013). Thus, a 
similar quality of protein produced from cell pools and cell lines will increase the 
possibility of using cell pools for the production of material for clinical trials, thereby 
reducing the time-frame to get the product to market.  
7.2.2. Co-transfection of donor vector with mRNA of transposase 
In this study, a helper vector coding for the transposase was used for gene delivery and the 
enzyme was transiently expressed. The main drawback of using a helper vector for 
expression of the transposase is the possibility of integration of the transposase gene into 
the genome, even though the vector does not carry a selection marker. Another 
disadvantage of this approach is the presence of the helper plasmid for several days post-
transfection. This could result in continued transient expression of the transposase and 
remobilization of the integrated transposons, potentially leading to genotoxicity. Thus, 




generation of transposon-mediated cell lines by using a helper vector for transposase 
expression would require the cell lines to be tested for transposase activity and integrated 
copies of the transposase, adding an extra step to the characterization of production cell 
lines.  
This could be avoided by delivering the transposase gene as an mRNA. This method has 
been shown to eliminate the risk of long-lasting side effects due to the rapid degradation of 
exogenous mRNA by cellular RNases and lack of integration into the genome of transfected 
HeLa cells (Bire et al. 2013a). Delivery of the transposase mRNA reduced the persistence 
of the transposase to a narrow window peaking at 18 h post-transfection with only traces 
of the mRNA remaining at 48 h post-transfection. On the other hand, the intracellular 
amount of transposase in transfection using helper vector peaked at 36 h post-transfection 
and then its level plateaued (Bire et al. 2013b). The delivery of the transposase gene as an 
mRNA needs to be explored in CHO cells for the generation of cell pools and cell lines, 
thereby improving their biosafety. This would eliminate any concerns of integration of the 
transposase gene, thereby making it a more reliable system to use for the generation of 
commercial cell lines. 
7.2.3. Combining transposons with other technologies 
One of the advantages of transposon systems is that they can be used in combination with 
other technologies targeting transcriptional, translational, or post-translational 
improvements in protein production.  
The construction of the artificial transposon in this study uncoupled the expression of the 
selection marker and the GOI by placing them under different promoters. Methods such as 
IRES-containing polycistronic genes or polyproteins could also be combined with 
transposon systems for co-expression of the selection marker downstream of the transgene 
in a polycistronic format. This strategy may increase the stringency of selection and also 
improve the homogeneity of protein production in cell pools, potentially improving the 
volumetric productivity and production stability. These methods could also be used to 
generate artificial transposons expressing different subunits of a multi-subunit protein 
complex. Combining the ideas of co-expressing multiple transgenes from a single artificial 




transposon and co-transfecting cells with multiple artificial transposons, can potentially 
simplify the expression of large multi-subunit protein complexes. 
Cis-regulating elements such as S/MAR and UCOE are known to increase protein yields 
and the stability of transgene expression in mammalian cells by promoting position-
independent transgene expression (Benton et al. 2002; Dharshanan et al. 2014; Grandjean 
et al. 2011; Kwaks and Otte 2006). Transposon systems can be used along with these cis-
regulating elements to attempt to improve the stability of protein production over time in 
cell pools. Use of S/MAR-containing artificial PB transposons has been shown to improve 
the volumetric productivity of an antibody in mesoangioblasts and CHO-M cells (Ley et 
al. 2013; Ley et al. 2014).  
7.2.4. Investigation of the transposon integration locus in CHO cells 
There have been several studies comparing the activities and integration profiles of PB, 
Tol2, and SB transposon systems in human cells for applications in gene therapy 
(Grabundzija et al. 2010; Huang et al. 2010; Meir et al. 2011; Wu et al. 2006). Comparisons 
of integration profiles of the three TP systems in human cells showed that the PB and Tol2 
transposons integrate in intragenic regions and near transcriptional start sites whereas the 
SB transposon integrated with apparent randomness across the genome within 
transcriptionally active regions (Grabundzija et al. 2010; Huang et al. 2010; Meir et al. 
2011). Studies exploring the integration locus of these transposon systems have not been 
conducted in recombinant CHO cell lines. Recent studies have determined the genome 
sequence of the CHO-K1, -DG44, and –S strains (Lewis et al. 2013; Xu et al. 2011). This 
major milestone can be utilized to investigate the preferential integration sites for the three 
transposon systems. This information would give further insight into the functioning of the 
transposon systems and would help improve their validity for commercial recombinant 
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• Scientific expertise in transposition mediated stable CHO cell pool and clone generation  
• Experienced with working in multi-cultural teams both as a leader and a team member 
• Successfully planned and supervised multiple master thesis projects and semester projects 
 
Education and Research Experience 
 
École Polytechnique Fédérale de Lausanne, Switzerland (EPFL)  
Doctoral Studies, Laboratory of Cellular Biotechnology (LBTC)            Oct 2011 – Present 
  
 Development of rapid and high titer process for generation of stable CHO pools and clones 
by piggyBac transposition for recombinant protein production  
 Comprehensive analysis of piggyBac, sleeping beauty and tol2 transposases in suspension 
adapted CHO DG44, CHO-K1 and CHO-S for the generation of stable pools 
 Investigation of single step transposition system for generation of pools and clones 
expressing multiple proteins simultaneously  
  
Master Thesis, Laboratory of Cellular Biotechnology (LBTC)       July 2010 – May 2011 
  
 Optimization of experimental conditions for generation of recombinant pools in CHO cells 
using piggyBac transposon system  
  
University of Cologne, Germany  
Research Intern, Institute for Genetics          May 2009 – July 2009 
  
• Successfully cloned and purified both Irga8 and Irgb10 of the IRG family which have been 
documented as participating in resistance to T. Gondii  
  
Birla Institute of Technology and Science, India (BITS) 
Integrated course               Jan 2006 – May 2011 
MSc (Hons). Biological Sciences and BE (Hons) in Computer Science        CGPA: 8.2/10 
• Ranked first in the department of Biological Sciences (30 students) 
  
Scientific Project – Microbial Fuel Cell (MFC)          Jan 2008 – May 2009 
• Designed a low cost fuel cell based on sewage water and water plants with 10% improved 
efficiency. 
  
Scientific Project – Computational genomics of skin cancer                    Aug 2008 – Dec 2008 
• Proposed a mathematical 3-parameter model to characterize the coding sequence of the myc 
gene and its mutants into a numerical values to develop a computational prediction for gene 









Research Intern             May 2008 – July 2008 
• Analyzed the various quality control techniques used for the production of several vaccines 
including Hepatitis B vaccine.  
  
Awards and Scholarships 
• Secured scholarship to present scientific posters at the Cell culture engineering XIV 
conference, 2014, PEACE conference, 2013 and ESACT conference, 2013 
• Awarded the prestigious DAAD-WISE scholarship for undergraduate students, 2009 
• National runner up in The Al Gore Sustainable Technology Venture Competition at Indian 
Institute of Technology  
• Presented a working prototype of Microbial Fuel Cell to Dr. A P J Abdul Kalam (ex-
President of India) as one of the top 10 projects of BITS-Pilani 
 
Manuscripts Published/In preparation 
• Alattia Jean-René, Mattia Matasci, Mitko Dimitrov, Lorène Aeschbach, Sowmya 
Balasubramanian, David Hacker, Florian Wurm, and Patrick Fraering. 2013. Highly 
efficient production of the Alzheimer's γ-Secretase integral membrane protease 
complex by a multi-gene stable integration approach. Biotechnol Bioeng. 110,7:1995-
2005. 
• Sowmya Balasubramanian, Mattia Matasci, Zuzana Kadlecova, Lucia Baldi, David 
Hacker, Florian Wurm. Rapid recombinant protein production from piggyBac 
transposon-mediated stable CHO cell pools. 
• Sowmya Balasubramanian, Yashas Rajendra, Lucia Baldi, David Hacker, Florian Wurm. 
Comparison of three transposons for the generation of highly productive recombinant 
CHO cell pools and cell lines. (In preparation) 
• Sowmya Balasubramanian, Lucia Baldi, David Hacker, Florian Wurm. Cell pools 
expressing multiple transgenes using the piggyBac transposon for gene delivery. (In 
preparation)  
• Sowmya Balasubramanian, Antonija Sakic, Lucia Baldi, David Hacker, Florian Wurm. 
Study of PiggyBac, Tol2 and Sleeping Beauty transposons for cell pool generation in 
different CHO cell strains. (In preparation) 
 
Conference Posters 
• POSTER - Comparison of PiggyBac mediated cell pool generation with different CHO host 
systems – CCE XIV 2014, Quebec City, Canada 
• POSTER - Synthetic transposons for the generation of stable CHO cell pools expressing 
recombinant proteins – PEACE 2013, Kananaskis, Canada 
• POSTER - PiggyBac transposition for the generation of stable CHO-DG44 cell pools 
expressing multiple transgenes – ESACT 2013, Lille, France 
• POSTER - PiggyBac transposon-mediated integration of transgenes in CHO-DG44 cells – 
ESACT 2011, Vienna, Austria 
  
Sowmya Balasubramanian 




• Mammalian cell culture, Transfection, Molecular Cloning, Quantitative RT-PCR, ELISA, 




• Teaching Assistant for the EPFL team at the International Genetically Engineered Machine 
competition (iGEM), 2012 
• Successfully trained 5 master students for semester projects or master thesis at EPFL 
• Member of Abhigyan: an education for all initiative of BITS (India) – Taught English, 
Hindi and Mathematics to 3 illiterate people for over 3 semesters 
• Member of core organizing committee for Quark, 2010 – Technical festival of BITS, Goa 
• Trained professionally for 4 years in Indian classical music 
• Fluent in English, Hindi, Tamil, Telugu and elementary proficiency in French, Malayalam, 
Marathi 
 
